<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Sci Rep</journal-id><journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id><journal-id journal-id-type="pmc-domain-id">1579</journal-id><journal-id journal-id-type="pmc-domain">scirep</journal-id><journal-title-group><journal-title>Scientific Reports</journal-title></journal-title-group><issn pub-type="epub">2045-2322</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10582156</article-id><article-id pub-id-type="pmcid-ver">PMC10582156.1</article-id><article-id pub-id-type="pmcaid">10582156</article-id><article-id pub-id-type="pmcaiid">10582156</article-id><article-id pub-id-type="pmid">37848606</article-id><article-id pub-id-type="doi">10.1038/s41598-023-45031-4</article-id><article-id pub-id-type="publisher-id">45031</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Incidence of rhabdomyolysis occurrence in psychoactive substances intoxication: a systematic review and meta-analysis</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-1056-5438</contrib-id><name name-style="western"><surname>Amanollahi</surname><given-names initials="A">Alireza</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-5914-7881</contrib-id><name name-style="western"><surname>Babeveynezhad</surname><given-names initials="T">Tannaz</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-0608-7840</contrib-id><name name-style="western"><surname>Sedighi</surname><given-names initials="M">Mohsen</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-9401-0781</contrib-id><name name-style="western"><surname>Shadnia</surname><given-names initials="S">Shahin</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-2485-7693</contrib-id><name name-style="western"><surname>Akbari</surname><given-names initials="S">Sadaf</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-8438-7956</contrib-id><name name-style="western"><surname>Taheri</surname><given-names initials="M">Mahbobeh</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-5534-452X</contrib-id><name name-style="western"><surname>Besharatpour</surname><given-names initials="M">Mahboobeh</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-5265-6237</contrib-id><name name-style="western"><surname>Jorjani</surname><given-names initials="G">Goljamal</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-3526-4375</contrib-id><name name-style="western"><surname>Salehian</surname><given-names initials="E">Elham</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-4005-9563</contrib-id><name name-style="western"><surname>Etemad</surname><given-names initials="K">Koorosh</given-names></name><address><email>etemadk@sbmu.ac.ir</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-9837-4956</contrib-id><name name-style="western"><surname>Mehrabi</surname><given-names initials="Y">Yadollah</given-names></name><address><email>ymehrabi@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/034m2b326</institution-id><institution-id institution-id-type="GRID">grid.411600.2</institution-id><institution>Department of Epidemiology, School of Public Health and Safety, </institution><institution>Shahid Beheshti University of Medical Sciences, </institution></institution-wrap>Tehran, Iran </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01kzn7k21</institution-id><institution-id institution-id-type="GRID">grid.411463.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 0706 2472</institution-id><institution>Pharmaceutical Sciences Branch, </institution><institution>Tehran Azad University, </institution></institution-wrap>Tehran, Iran </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03w04rv71</institution-id><institution-id institution-id-type="GRID">grid.411746.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 4911 7066</institution-id><institution>Trauma and Injury Research Center, </institution><institution>Iran University of Medical Sciences, </institution></institution-wrap>Tehran, Iran </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/034m2b326</institution-id><institution-id institution-id-type="GRID">grid.411600.2</institution-id><institution>Department of Clinical Toxicology, Loghman Hakim Hospital, </institution><institution>Shahid Beheshti University of Medical Sciences, </institution></institution-wrap>Tehran, Iran </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/036jqmy94</institution-id><institution-id institution-id-type="GRID">grid.214572.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8294</institution-id><institution>Department of Internal Medicine, Division of Nephrology, Carver College of Medicine, </institution><institution>University of Iowa, </institution></institution-wrap>Iowa City, IA USA </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/034m2b326</institution-id><institution-id institution-id-type="GRID">grid.411600.2</institution-id><institution>Skull Base Research Center, Loghman Hakim Hospital, </institution><institution>Shahid Beheshti University of Medical Sciences, </institution></institution-wrap>Tehran, Iran </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/034m2b326</institution-id><institution-id institution-id-type="GRID">grid.411600.2</institution-id><institution>Resources Development Deputy, </institution><institution>Shahid Beheshti University of Medical Sciences, </institution></institution-wrap>Tehran, Iran </aff></contrib-group><pub-date pub-type="epub"><day>17</day><month>10</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>13</volume><issue-id pub-id-type="pmc-issue-id">425018</issue-id><elocation-id>17693</elocation-id><history><date date-type="received"><day>17</day><month>10</month><year>2022</year></date><date date-type="accepted"><day>14</day><month>10</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>17</day><month>10</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>19</day><month>10</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-01-27 13:25:18.193"><day>27</day><month>01</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2023</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="41598_2023_Article_45031.pdf"/><abstract id="Abs1"><p id="Par1">Rhabdomyolysis is a potentially life-threatening condition induced by diverse mechanisms including drugs and toxins. We aimed to investigate the incidence of rhabdomyolysis occurrence in intoxicated patients with psychoactive substances. In this review, three databases (PubMed, Scopus, Web of Science) and search engine (Google Scholar) were searched by various keywords. After the screening of retrieved documents, related data of included studies were extracted and analyzed with weighted mean difference (WMD) in random effect model. The highest incidence of rhabdomyolysis was observed in intoxication with heroin (57.2 [95% CI 22.6&#8211;91.8]), amphetamines (30.5 [95% CI 22.6&#8211;38.5]), and cocaine (26.6 [95% CI 11.1&#8211;42.1]). The pooled effect size for blood urea nitrogen (WMD&#8201;=&#8201;8.78, p&#8201;=&#8201;0.002), creatinine (WMD&#8201;=&#8201;0.44, p&#8201;&lt;&#8201;0.001), and creatinine phosphokinase (WMD&#8201;=&#8201;2590.9, p&#8201;&lt;&#8201;0.001) was high in patients with rhabdomyolysis compared to patients without rhabdomyolysis. Our results showed a high incidence of rhabdomyolysis induced by psychoactive substance intoxication in ICU patients when compared to total wards. Also, the incidence of rhabdomyolysis occurrence was high in ICU patients with heroin and amphetamine intoxication. Therefore, clinicians should anticipate this complication, monitor for rhabdomyolysis, and institute appropriate treatment protocols early in the patient&#8217;s clinical course.</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Kidney</kwd><kwd>Toxicology</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Nature Limited 2023</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">Psychoactive substances affect thinking, emotion, mood and behavior, and consciousness after being consumed and are classified into central nervous system depressants (ethanol, opioids, cannabis), central nervous system stimulants (amphetamines, cocaine), hallucinogens (LSD), and empathogens (ecstasy)<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. Nausea, vomiting, agitation, anxiety, and drowsiness are the most common adverse effects of psychoactive drugs but serious conditions such as psychosis, delirium, seizure, cardiotoxicity, severe lung injury, and acute kidney injury (AKI) due to rhabdomyolysis have seen reported in abusers<sup><xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR3">3</xref></sup>.</p><p id="Par3">Previous studies have documented drug induced-rhabdomyolysis owing to the overuse of methanol, ethanol, methadone, opioid, cocaine, amphetamine, methamphetamine, ecstasy, synthetic cannabinoids, heroin, and tramadol<sup><xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR5">5</xref></sup>. Rhabdomyolysis is a syndrome characterized by muscle necrosis and the release of intracellular muscle constituents into circulation<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>. Creatine Phosphokinase (CPK) level commonly increases and muscle pain and myoglobinuria may be identified. The severity of rhabdomyolysis ranges from asymptomatic elevation in serum muscle enzymes to life-threatening conditions associated with extreme enzyme elevation, electrolyte imbalance, and acute kidney injury (AKI)<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>.</p><p id="Par4">Rhabdomyolysis has been reported in a growing number of studies as one of the worst results of drug poisoning but with different incidences<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>. For instance, the incidence of cocaine-induced rhabdomyolysis is reported from 25<sup><xref ref-type="bibr" rid="CR9">9</xref></sup> to 46.7%<sup><xref ref-type="bibr" rid="CR10">10</xref></sup> and this value for methadone is between 14.7<sup><xref ref-type="bibr" rid="CR11">11</xref></sup> and 34.6%<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>.</p><p id="Par5">Considering the increasing use of psychoactive substances in recent years and little known about drug-induced rhabdomyolysis in abusers, screening and assessing the incidence of rhabdomyolysis and proper management is essential. For this reason, we systematically reviewed the international databases in this study and the results of related papers were pooled regarding the incidence of rhabdomyolysis in hospitalized patients with intoxication.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study design</title><p id="Par6">This systematic review and meta-analysis study was according to the Preferred Reporting Items in Systematic Reviews and Meta-Analyses (PRISMA) guideline<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>, and protocol of the study was registered in PROSPERO (CRD42022326206).</p></sec><sec id="Sec4"><title>Search strategy</title><p id="Par7">To find related publications, a combination of related keywords was used in databases and search engine including PubMed, Scopus, Web of Science, and Google Scholar. In addition, we used a manual search to develop literature search, references of selected studies, and citations of studies. The final search was updated on July 15, 2022 before data analysis. The keywords used included a combination of suggested words by Medical Subject Heading (MeSH) and other related words, as represented in details in Table <xref rid="Tab1" ref-type="table">1</xref>. Finally, three limitations in research including human studies, publication date (2000&#8211;2022), and English language studies were applied. All processes related to the literature search were done independently by two researchers (AA and ES).<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>The search strategy in all databases/search engine.</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left" colspan="1" rowspan="1">PubMed</td><td align="left" colspan="1" rowspan="1">(rhabdomyolys*[tw] OR rhabdomyolysis[mh] OR "creatine phosphokinase"[tw] OR "creatine kinase"[tw] OR cpk[tw] OR ck[tw]) AND ("toxic*"[tw] OR "toxic actions"[mh] OR overdose*[tw] OR drug overdose[mh] OR opiate overdose[mh] OR abuse[tw] OR Substance-Related Disorders[mh] OR poisons[mh] OR poisoning[tw] OR Poisoning[mh] OR intoxication[tw] OR intoxicat*[tw]) AND (opioid*[tw] OR opium*[tw] OR cannabis[tw] OR Marijuana[tw] OR Heroin[tw] OR amphetamine*[tw] OR methamphetamine*[tw] OR ecstasy[tw] OR MDMA[tw] OR methadone[tw] OR tramadol[tw] OR ethanol[tw] OR methanol[tw] OR "Alcoholic Intoxication"[mh] OR synthetic cannabinoid*[tw] OR psychoactive substance*[tw]) NOT (review[tiab] OR review[pt])</td></tr><tr><td align="left" colspan="1" rowspan="1">Scopus</td><td align="left" colspan="1" rowspan="1">((ALL (overdose) OR ALL (abuse) OR ALL (poison) OR ALL (poisoning) OR ALL (intoxication))) AND ((ALL (opioid) OR ALL (opium) OR ALL (cannabis) OR ALL (marijuana) OR ALL (heroin) OR ALL (amphetamine$) OR ALL (methamphetamine) OR ALL (ecstasy) OR ALL (mdma) OR ALL (methadone) OR ALL (tramadol) OR ALL (cocaine) OR ALL (methanol) OR ALL (ethanol) OR ALL (synthetic AND cannabinoid) OR ALL (psychoactive AND substance))) AND ((ALL (rhabdomyolysis) OR ALL (rhabdomyolyse) OR ALL (creatine phosphokinase) OR ALL (creatine kinase))) AND (LIMIT-TO (DOCTYPE, "le") OR LIMIT-TO (DOCTYPE, "sh") OR LIMIT-TO (DOCTYPE, "ed") OR LIMIT-TO (DOCTYPE, "ar") OR LIMIT-TO (DOCTYPE, "cp"))</td></tr><tr><td align="left" colspan="1" rowspan="1">Web of sciences</td><td align="left" colspan="1" rowspan="1">((TS&#8201;=&#8201;(opioid OR opium OR cannabis OR marijuana OR heroin OR amphetamine OR methamphetamine OR ecstasy OR MDMA OR methadone OR tramadol OR cocaine OR methanol OR ethanol OR synthetic cannabinoids OR psychoactive substance)) AND (TS&#8201;=&#8201;(overdose OR abuse OR poison OR poisoning OR intoxication OR toxic)) AND (TS&#8201;=&#8201;(rhabdomyolysis OR rhabdomyolyse OR creatine phosphokinase OR creatine kinase)))</td></tr><tr><td align="left" colspan="1" rowspan="1">Google Scholar</td><td align="left" colspan="1" rowspan="1">This search strategy was repeated for all psychoactives and 300 initial results were reviewed; ((poisoning OR intoxication) AND (opioid) AND (rhabdomyolysis OR creatine kinase))</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec5"><title>Eligibility criteria</title><p id="Par8">Eligibility criteria were elaborated based on the PICO structure (Population, Intervention\ Exposure, Comparator, and Outcomes), and the studied population under meta-analysis were intoxicated patients hospitalized in the intensive care unit (ICU) or general wards due to poisoning, overdose, and abuse and were either conscious or unconscious. Intoxicated patients following enteral, parenteral, and inhalational use of methadone, cocaine, heroin, tramadol, amphetamine, methamphetamine, ecstasy, MDMA (3,4-methylenedioxyamphetamine), opioid, synthetic cannabinoids, methanol, and ethanol were included in the study. Mono-intoxication means patients who were intoxicated with a single substance and multi-intoxication means patients who had co-exposure and concomitant substances were detected in their drug screen. The research question of the study was occurrence of rhabdomyolysis among hospitalized intoxicated patients. Exclusion criteria were case reports and case series with less than 5 samples, review or editorial articles, none English language manuscripts, and studies on children.</p></sec><sec id="Sec6"><title>Study selection, data items, data collection</title><p id="Par9">Retrieved observational studies from selected databases with relevant exposures were imported into EndNote citation management software. After removing duplicate studies, title and abstract of remained studies were screened and data extraction was done by two independent researchers (TB and SA). Data extraction forms contained the author's name, year, age, gender, country, continent, study design, type of psychoactive drug, sample size, type of hospitalization wards (ICU/total wards), multi-intoxication (yes/no), dose of substance, and patient&#8217;s medical history. Also, subgroup analyses for hospitalization ward, multi-intoxication, and geographical area (based on World Health Organization regions) was performed. In subgroup analysis, ICU means studies that included only ICU patients and total wards mean studies reporting total patients hospitalized in ICU and general wards. Also, poisoning with multiple drugs means studies reporting overall occurrence of rhabdomyolysis for all intoxicated patients but did not determine the incidence of rhabdomyolysis separately for each substance. Rhabdomyolysis occurrence was defined if included patients had CPK&#8201;&gt;&#8201;1000&#160;IU/L/ or CPK&#8201;&gt;&#8201;5&#8201;&#215;&#8201;ULN<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>. Any disagreement at each stage was checked by a third researcher (AA).</p></sec><sec id="Sec7"><title>Risk of bias of included studies</title><p id="Par10">The risk of bias in studies was assessed independently by two researchers (MB and MS) and disagreements were discussed and checked by the third researcher (KE). For this purpose, Newcastle&#8211;Ottawa scale (NOS) was used to assess quality of nonrandomized studies in meta-analyses and the number of stars indicated methodological quality of articles.</p></sec><sec id="Sec8"><title>Synthesis of results</title><p id="Par11">The number of intoxicated patients in the studies was considered as denominator of the fraction and the number of samples containing occurrence of rhabdomyolysis was placed in the numerator. The effect size for rhabdomyolysis incidence in each subgroup was determined as pooled effect size with 95% confidence interval (CI). Weighted mean difference (WMD) was used to compare values of renal function indexes including blood urea nitrogen (BUN), creatinine (Cr), and CPK between intoxicated patients with and without rhabdomyolysis. The pooled effects size was estimated using random effect model by considering disparities between studies. Heterogeneity between studies was estimated by Cochrane Q test and I<sup>2</sup> index. The type of hospitalization wards, geographical area, and multi-intoxication were considered to find the source of heterogeneity in the subgroup analysis. Publication bias was determined by Egger&#8217;s regression and Begg&#8217;s test. Sensitivity analysis was performed to assess the impact of a single study on the results. All statistical analyses for meta-analysis were done in Stata software (version 16.0; Stata Corporation).</p></sec></sec><sec id="Sec9"><title>Results</title><sec id="Sec10"><title>Study selection and characteristics</title><p id="Par12">The process of study selection is depicted in the PRISMA flow diagram (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). In the systematic search of electronic databases, 2493 nonredundant studies were found, of which 62 articles were potentially relevant. After reading their full texts, 5 articles were excluded due to lack of required data and 57 articles met the inclusion criteria for final analysis.<fig id="Fig1" position="float" orientation="portrait"><label>Figure 1</label><caption><p>Flow diagram of the literature search for studies included in meta-analysis.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="41598_2023_45031_Fig1_HTML.jpg"/></fig></p><p id="Par13">As described in Table <xref rid="Tab2" ref-type="table">2</xref>, the percentage of hospitalized men in all included studies was high compared to women. The minimum and maximum mean age of patients was 19.4 and 46.0&#160;years, respectively. The reported median age ranged from 19 to 50&#160;years. A summary of included article characteristics is described in Table <xref rid="Tab2" ref-type="table">2</xref>. Based on the types of psychoactive substances, a total of 57 articles containing 3,122,944 intoxicated patients were screened. Included articles were 11 studies for opioids, 6 for methadone, 11 for synthetic cannabinoids, 7 for cocaine, 17 for amphetamines, 5 for methanol, 4 for ethanol, 4 for heroin, 2 for tramadol, and 15 for multiple drugs. Most of the studies were done in the United States (n&#8201;=&#8201;24), Iran (n&#8201;=&#8201;13), Canada (n&#8201;=&#8201;3), and Australia (n&#8201;=&#8201;3).<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Characteristics of the studies included in the systematic review and meta-analysis.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">ID</th><th align="left" colspan="1" rowspan="1">Author/reference</th><th align="left" colspan="1" rowspan="1">Year</th><th align="left" colspan="1" rowspan="1">Country continent</th><th align="left" colspan="1" rowspan="1">Design</th><th align="left" colspan="1" rowspan="1">Age*</th><th align="left" colspan="1" rowspan="1">Sex</th><th align="left" colspan="1" rowspan="1">Sample size</th><th align="left" colspan="1" rowspan="1">Poisoning drug</th><th align="left" colspan="1" rowspan="1">Participants</th><th align="left" colspan="1" rowspan="1">Multi-intoxication</th><th align="left" colspan="1" rowspan="1">Dose</th><th align="left" colspan="1" rowspan="1">Route of administration</th><th align="left" colspan="1" rowspan="1">PMH</th><th align="left" colspan="1" rowspan="1">Risk of bias</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">Aghabiklooei<sup><xref ref-type="bibr" rid="CR15">15</xref></sup></td><td align="left" colspan="1" rowspan="1">2014</td><td align="left" colspan="1" rowspan="1">Iran/EM</td><td align="left" colspan="1" rowspan="1">Cross-sectional</td><td align="left" colspan="1" rowspan="1">36.0&#8201;&#177;&#8201;15.8</td><td align="left" colspan="1" rowspan="1">(74.8%)M/(25.2%)F</td><td align="left" colspan="1" rowspan="1">322</td><td align="left" colspan="1" rowspan="1">Methadone</td><td align="left" colspan="1" rowspan="1">2007&#8211;2012/total hospitalized</td><td align="left" colspan="1" rowspan="1">No</td><td align="left" colspan="1" rowspan="1">85.91&#8201;&#177;&#8201;82.61 (mg)</td><td align="left" colspan="1" rowspan="1">Oral</td><td align="left" colspan="1" rowspan="1">No</td><td align="left" colspan="1" rowspan="1">*******</td></tr><tr><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">Arefi<sup><xref ref-type="bibr" rid="CR16">16</xref></sup></td><td align="left" colspan="1" rowspan="1">2014</td><td align="left" colspan="1" rowspan="1">Iran/EM</td><td align="left" colspan="1" rowspan="1">Cross-sectional</td><td align="left" colspan="1" rowspan="1">30.55&#8201;&#177;&#8201;15.8</td><td align="left" colspan="1" rowspan="1">(52%)M/(48%)F</td><td align="left" colspan="1" rowspan="1">1500</td><td align="left" colspan="1" rowspan="1">Multiple drugs/opium/alcohol/sedative</td><td align="left" colspan="1" rowspan="1">During year 2010/total hospitalized</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">Oral/IV/inhalation</td><td align="left" colspan="1" rowspan="1">No</td><td align="left" colspan="1" rowspan="1">********</td></tr><tr><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">Armenian<sup><xref ref-type="bibr" rid="CR17">17</xref></sup></td><td align="left" colspan="1" rowspan="1">2012</td><td align="left" colspan="1" rowspan="1">USA/America</td><td align="left" colspan="1" rowspan="1">Case series</td><td align="left" colspan="1" rowspan="1">22.42 mean (19&#8211;35)</td><td align="left" colspan="1" rowspan="1">(58.3%)M/(41.7%)F</td><td align="left" colspan="1" rowspan="1">12</td><td align="left" colspan="1" rowspan="1">AMPH/MDMA</td><td align="left" colspan="1" rowspan="1">May 30, 2010/ICU hospitalized</td><td align="left" colspan="1" rowspan="1">No</td><td align="left" colspan="1" rowspan="1">0.75&#8201;&#177;&#8201;0.48 (mg/l)</td><td align="left" colspan="1" rowspan="1">Oral</td><td align="left" colspan="1" rowspan="1">No</td><td align="left" colspan="1" rowspan="1">*****</td></tr><tr><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">Azarakhshi<sup><xref ref-type="bibr" rid="CR18">18</xref></sup></td><td align="left" colspan="1" rowspan="1">2021</td><td align="left" colspan="1" rowspan="1">Iran/EM</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">38.26&#8201;&#177;&#8201;25.91</td><td align="left" colspan="1" rowspan="1">(75.8%)M/(24.2%)F</td><td align="left" colspan="1" rowspan="1">227</td><td align="left" colspan="1" rowspan="1">Opium</td><td align="left" colspan="1" rowspan="1">Mar 2006&#8211;Mar 2016/total hospitalized</td><td align="left" colspan="1" rowspan="1">No</td><td align="left" colspan="1" rowspan="1">4456&#8201;&#177;&#8201;10,317 (mg)</td><td align="left" colspan="1" rowspan="1">Oral</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">******</td></tr><tr><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">Brahmi<sup><xref ref-type="bibr" rid="CR19">19</xref></sup></td><td align="left" colspan="1" rowspan="1">2007</td><td align="left" colspan="1" rowspan="1">Tunisia/WP</td><td align="left" colspan="1" rowspan="1">Case series</td><td align="left" colspan="1" rowspan="1">21.5 mean (16&#8211;53)</td><td align="left" colspan="1" rowspan="1">(93.75%)M/(6.25%)F</td><td align="left" colspan="1" rowspan="1">16</td><td align="left" colspan="1" rowspan="1">Methanol</td><td align="left" colspan="1" rowspan="1">Dec 2003&#8211;Apr 2004/ICU hospitalized</td><td align="left" colspan="1" rowspan="1">No</td><td align="left" colspan="1" rowspan="1">250&#160;ml (range 30&#8211;1000)</td><td align="left" colspan="1" rowspan="1">Oral</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">******</td></tr><tr><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">Bruggisser<sup><xref ref-type="bibr" rid="CR20">20</xref></sup></td><td align="left" colspan="1" rowspan="1">2009</td><td align="left" colspan="1" rowspan="1">Switzerland/Europe</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">29.21&#8201;&#177;&#8201;12.54</td><td align="left" colspan="1" rowspan="1">(61.3%)M/(38.7%)F</td><td align="left" colspan="1" rowspan="1">220</td><td align="left" colspan="1" rowspan="1">MDMA/cocaine/AMPH</td><td align="left" colspan="1" rowspan="1">1997 and 2009/total hospitalized</td><td align="left" colspan="1" rowspan="1">No</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">Oral/nasal/IV/inhalation</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">*******</td></tr><tr><td align="left" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">Burton<sup><xref ref-type="bibr" rid="CR21">2</xref><xref ref-type="bibr" rid="CR21">1</xref></sup></td><td align="left" colspan="1" rowspan="1">2019</td><td align="left" colspan="1" rowspan="1">USA/America</td><td align="left" colspan="1" rowspan="1">Cross-sectional</td><td align="left" colspan="1" rowspan="1">50 median (34&#8211;60)</td><td align="left" colspan="1" rowspan="1">(47.2%)M/(52.8%)F</td><td align="left" colspan="1" rowspan="1">570,987</td><td align="left" colspan="1" rowspan="1">Opium/methadone/heroin/other opiates/narcotic</td><td align="left" colspan="1" rowspan="1">In 2010&#8211;2014/total hospitalized</td><td align="left" colspan="1" rowspan="1">Cocaine/AMPH/BDZ/aromatic analgesic</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">HTN/MDD/Psychiatric/AKI</td><td align="left" colspan="1" rowspan="1">********</td></tr><tr><td align="left" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">Caldicott<sup><xref ref-type="bibr" rid="CR22">2</xref><xref ref-type="bibr" rid="CR22">2</xref></sup></td><td align="left" colspan="1" rowspan="1">2003</td><td align="left" colspan="1" rowspan="1">Australia/WP</td><td align="left" colspan="1" rowspan="1">Case series</td><td align="left" colspan="1" rowspan="1">25 mean</td><td align="left" colspan="1" rowspan="1">(57.9%)M/(42.1%)F</td><td align="left" colspan="1" rowspan="1">19</td><td align="left" colspan="1" rowspan="1">MDMA/PMA</td><td align="left" colspan="1" rowspan="1">Jan 1999&#8211;Dec 2001/total hospitalized</td><td align="left" colspan="1" rowspan="1">BARB/THC/BDZ</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">Oral</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">*****</td></tr><tr><td align="left" colspan="1" rowspan="1">9</td><td align="left" colspan="1" rowspan="1">Chhabra<sup><xref ref-type="bibr" rid="CR23">23</xref></sup></td><td align="left" colspan="1" rowspan="1">2017</td><td align="left" colspan="1" rowspan="1">USA/America</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">21 median (19.5&#8211;24)</td><td align="left" colspan="1" rowspan="1">(53.6%)M/(46.4%)F</td><td align="left" colspan="1" rowspan="1">28</td><td align="left" colspan="1" rowspan="1">Ethanol/ecstasy/marijuana/LSD/cocaine</td><td align="left" colspan="1" rowspan="1">The 3-day/total hospitalized</td><td align="left" colspan="1" rowspan="1">No</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">Oral</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">*****</td></tr><tr><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">Dabby<sup><xref ref-type="bibr" rid="CR24">24</xref></sup></td><td align="left" colspan="1" rowspan="1">2006</td><td align="left" colspan="1" rowspan="1">Israel/Europe</td><td align="left" colspan="1" rowspan="1">Research report</td><td align="left" colspan="1" rowspan="1">29.5 mean (22&#8211;42)</td><td align="left" colspan="1" rowspan="1">(100%)M</td><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">Heroin</td><td align="left" colspan="1" rowspan="1">In 2001 and 2005/total hospitalized</td><td align="left" colspan="1" rowspan="1">No</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">Sniffing/IV</td><td align="left" colspan="1" rowspan="1">Hepatitis C</td><td align="left" colspan="1" rowspan="1">*****</td></tr><tr><td align="left" colspan="1" rowspan="1">11</td><td align="left" colspan="1" rowspan="1">Forrester<sup><xref ref-type="bibr" rid="CR25">25</xref></sup></td><td align="left" colspan="1" rowspan="1">2021</td><td align="left" colspan="1" rowspan="1">USA/America</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">23 mean (12&#8211;67)</td><td align="left" colspan="1" rowspan="1">(74.2%)M/(25.8%)F</td><td align="left" colspan="1" rowspan="1">454</td><td align="left" colspan="1" rowspan="1">Synthetic cannabinoids</td><td align="left" colspan="1" rowspan="1">During 2010/total hospitalized</td><td align="left" colspan="1" rowspan="1">Alcohol/alprazolam/cocaine/acetaminophen</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">Inhalation/oral</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">******</td></tr><tr><td align="left" colspan="1" rowspan="1">12</td><td align="left" colspan="1" rowspan="1">Gilley<sup><xref ref-type="bibr" rid="CR26">26</xref></sup></td><td align="left" colspan="1" rowspan="1">2021</td><td align="left" colspan="1" rowspan="1">USA/America</td><td align="left" colspan="1" rowspan="1">Prospectively</td><td align="left" colspan="1" rowspan="1">16 to 19</td><td align="left" colspan="1" rowspan="1">(91%)M/(9%)F</td><td align="left" colspan="1" rowspan="1">75</td><td align="left" colspan="1" rowspan="1">Synthetic cannabinoids</td><td align="left" colspan="1" rowspan="1">Sep 2008&#8211;Feb 2011/total hospitalized</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">******</td></tr><tr><td align="left" colspan="1" rowspan="1">13</td><td align="left" colspan="1" rowspan="1">Greene<sup><xref ref-type="bibr" rid="CR27">27</xref></sup></td><td align="left" colspan="1" rowspan="1">2003</td><td align="left" colspan="1" rowspan="1">England/Europe</td><td align="left" colspan="1" rowspan="1">Case series</td><td align="left" colspan="1" rowspan="1">19.4 mean (17&#8211;23)</td><td align="left" colspan="1" rowspan="1">(85.7%)M/(14.3%)F</td><td align="left" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">Ecstasy/MDMA</td><td align="left" colspan="1" rowspan="1">One day between the hours of 6 and 8 AM/total hospitalized</td><td align="left" colspan="1" rowspan="1">No</td><td align="left" colspan="1" rowspan="1">0.63&#8201;&#177;&#8201;0.83 (mg/l)</td><td align="left" colspan="1" rowspan="1">Oral</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">*****</td></tr><tr><td align="left" colspan="1" rowspan="1">14</td><td align="left" colspan="1" rowspan="1">Halpern<sup><xref ref-type="bibr" rid="CR28">28</xref></sup></td><td align="left" colspan="1" rowspan="1">2010</td><td align="left" colspan="1" rowspan="1">Israel/Europe</td><td align="left" colspan="1" rowspan="1">Prospective</td><td align="left" colspan="1" rowspan="1">24.2&#8201;&#177;&#8201;6.3</td><td align="left" colspan="1" rowspan="1">(63%)M/(37%)F</td><td align="left" colspan="1" rowspan="1">52</td><td align="left" colspan="1" rowspan="1">Ecstasy/MDMA</td><td align="left" colspan="1" rowspan="1">Aug 2002&#8211;Feb 2003/total hospitalized</td><td align="left" colspan="1" rowspan="1">Alcohol/opiates/cocaine/cannabis/BDZ/LSD</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">Oral</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">******</td></tr><tr><td align="left" colspan="1" rowspan="1">15</td><td align="left" colspan="1" rowspan="1">Hermanns-Clausen<sup><xref ref-type="bibr" rid="CR29">29</xref></sup></td><td align="left" colspan="1" rowspan="1">2012</td><td align="left" colspan="1" rowspan="1">Germany/Europe</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">19 median (14&#8211;30)</td><td align="left" colspan="1" rowspan="1">(86.2%)M/(13.8%)F</td><td align="left" colspan="1" rowspan="1">29</td><td align="left" colspan="1" rowspan="1">Synthetic cannabinoids</td><td align="left" colspan="1" rowspan="1">Sep 2008&#8211;Feb 2011/total hospitalized</td><td align="left" colspan="1" rowspan="1">AMPH/BDZ/lorazepam/MAMP</td><td align="left" colspan="1" rowspan="1">10.99&#8201;&#177;&#8201;13.91 (ng/ml)</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">******</td></tr><tr><td align="left" colspan="1" rowspan="1">16</td><td align="left" colspan="1" rowspan="1">Heyerdahl<sup><xref ref-type="bibr" rid="CR30">3</xref><xref ref-type="bibr" rid="CR30">0</xref></sup></td><td align="left" colspan="1" rowspan="1">2008</td><td align="left" colspan="1" rowspan="1">Norway/Europe</td><td align="left" colspan="1" rowspan="1">Prospective cross-sectional</td><td align="left" colspan="1" rowspan="1">&#8201;&#8805;&#8201;16 years</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">947</td><td align="left" colspan="1" rowspan="1">Methanol/AMPH/opioids/ethanol/cocaine</td><td align="left" colspan="1" rowspan="1">Apr 2003&#8211;Mar 2004/total hospitalized</td><td align="left" colspan="1" rowspan="1">Codeine/paracetamol/BDZ/opioid</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">Oral</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">*******</td></tr><tr><td align="left" colspan="1" rowspan="1">17</td><td align="left" colspan="1" rowspan="1">Imam<sup><xref ref-type="bibr" rid="CR31">3</xref><xref ref-type="bibr" rid="CR31">1</xref></sup></td><td align="left" colspan="1" rowspan="1">2013</td><td align="left" colspan="1" rowspan="1">USA/America</td><td align="left" colspan="1" rowspan="1">Case series</td><td align="left" colspan="1" rowspan="1">35.4 mean (28&#8211;42)</td><td align="left" colspan="1" rowspan="1">(100%)M</td><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">AMPH</td><td align="left" colspan="1" rowspan="1">May&#8211;December 2011/ICU hospitalized</td><td align="left" colspan="1" rowspan="1">Cannabinoids/cocaine</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">Ingestion/smoke</td><td align="left" colspan="1" rowspan="1">Bipolar/ADHD/MDD/anxiety</td><td align="left" colspan="1" rowspan="1">*****</td></tr><tr><td align="left" colspan="1" rowspan="1">18</td><td align="left" colspan="1" rowspan="1">Isoardi<sup><xref ref-type="bibr" rid="CR32">32</xref></sup></td><td align="left" colspan="1" rowspan="1">2019</td><td align="left" colspan="1" rowspan="1">Australia/WP</td><td align="left" colspan="1" rowspan="1">Retrospective/observational</td><td align="left" colspan="1" rowspan="1">31 median (16&#8211;68)</td><td align="left" colspan="1" rowspan="1">(71%)M/(29%)F</td><td align="left" colspan="1" rowspan="1">329</td><td align="left" colspan="1" rowspan="1">MAMP</td><td align="left" colspan="1" rowspan="1">During 2016/total hospitalized</td><td align="left" colspan="1" rowspan="1">Alcohol/cannabis/BDZ/heroin/MDMA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">IV/inhalation/oral</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">******</td></tr><tr><td align="left" colspan="1" rowspan="1">19</td><td align="left" colspan="1" rowspan="1">Isoardi<sup><xref ref-type="bibr" rid="CR33">33</xref></sup></td><td align="left" colspan="1" rowspan="1">2020</td><td align="left" colspan="1" rowspan="1">Australia/WP</td><td align="left" colspan="1" rowspan="1">Prospective/observational</td><td align="left" colspan="1" rowspan="1">32 median (28&#8211;31)</td><td align="left" colspan="1" rowspan="1">(85.4%)M/(14.6%)F</td><td align="left" colspan="1" rowspan="1">48</td><td align="left" colspan="1" rowspan="1">MAMP</td><td align="left" colspan="1" rowspan="1">Dec 2017&#8211;Sep 2018/total hospitalized</td><td align="left" colspan="1" rowspan="1">Opioid/aspirin/ethanol/LSD/GHB/marijuana</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">IV/inhalation/oral</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">*******</td></tr><tr><td align="left" colspan="1" rowspan="1">20</td><td align="left" colspan="1" rowspan="1">Kaewput<sup><xref ref-type="bibr" rid="CR34">34</xref></sup></td><td align="left" colspan="1" rowspan="1">2020</td><td align="left" colspan="1" rowspan="1">USA/America</td><td align="left" colspan="1" rowspan="1">Retrospective cohort</td><td align="left" colspan="1" rowspan="1">37.9&#8201;&#177;&#8201;18.3</td><td align="left" colspan="1" rowspan="1">(69.5%)M/(30.5%)F</td><td align="left" colspan="1" rowspan="1">603</td><td align="left" colspan="1" rowspan="1">Methanol</td><td align="left" colspan="1" rowspan="1">From 1993&#8211;2014/total hospitalized</td><td align="left" colspan="1" rowspan="1">No</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">oral</td><td align="left" colspan="1" rowspan="1">ObesityHTN/CKD/DM</td><td align="left" colspan="1" rowspan="1">******</td></tr><tr><td align="left" colspan="1" rowspan="1">21</td><td align="left" colspan="1" rowspan="1">Kamijo<sup><xref ref-type="bibr" rid="CR35">35</xref></sup></td><td align="left" colspan="1" rowspan="1">2014</td><td align="left" colspan="1" rowspan="1">Japan/WP</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">28.4&#8201;&#177;&#8201;8.4</td><td align="left" colspan="1" rowspan="1">(82%)M/(18%)F</td><td align="left" colspan="1" rowspan="1">518</td><td align="left" colspan="1" rowspan="1">Synthetic cannabinoid</td><td align="left" colspan="1" rowspan="1">Jan 2006&#8211;Dec 2012/total hospitalized</td><td align="left" colspan="1" rowspan="1">Alcohol/BDZ psychotropic drug</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">Inhalation/ingestion/sniffing/anal</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">******</td></tr><tr><td align="left" colspan="1" rowspan="1">22</td><td align="left" colspan="1" rowspan="1">Kasper<sup><xref ref-type="bibr" rid="CR36">36</xref></sup></td><td align="left" colspan="1" rowspan="1">2018</td><td align="left" colspan="1" rowspan="1">USA/America</td><td align="left" colspan="1" rowspan="1">Case Reports</td><td align="left" colspan="1" rowspan="1">29 median (23.5&#8211;36.5)</td><td align="left" colspan="1" rowspan="1">(80%)M/(20%)F</td><td align="left" colspan="1" rowspan="1">56</td><td align="left" colspan="1" rowspan="1">Synthetic cannabinoids</td><td align="left" colspan="1" rowspan="1">Apr&#8211;May 2015/total hospitalized</td><td align="left" colspan="1" rowspan="1">Cannabinoids/BDZ cocaine/AMPH</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">HTN/seizure/mental illness</td><td align="left" colspan="1" rowspan="1">******</td></tr><tr><td align="left" colspan="1" rowspan="1">23</td><td align="left" colspan="1" rowspan="1">Katz<sup><xref ref-type="bibr" rid="CR37">37</xref></sup></td><td align="left" colspan="1" rowspan="1">2016</td><td align="left" colspan="1" rowspan="1">USA/America</td><td align="left" colspan="1" rowspan="1">Case series</td><td align="left" colspan="1" rowspan="1">22.36 mean (13&#8211;50)</td><td align="left" colspan="1" rowspan="1">(63.6%)M/(36.4%)F</td><td align="left" colspan="1" rowspan="1">11</td><td align="left" colspan="1" rowspan="1">Synthetic cannabinoids</td><td align="left" colspan="1" rowspan="1">Apr 2015/ICU hospitalized</td><td align="left" colspan="1" rowspan="1">Caffeine/morphine/midazolam/ethanol/AMPH/lorazepam</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">Hepatitis/bipolar/epilepsy</td><td align="left" colspan="1" rowspan="1">*****</td></tr><tr><td align="left" colspan="1" rowspan="1">24</td><td align="left" colspan="1" rowspan="1">Khoshideh<sup><xref ref-type="bibr" rid="CR38">3</xref><xref ref-type="bibr" rid="CR38">8</xref></sup></td><td align="left" colspan="1" rowspan="1">2017</td><td align="left" colspan="1" rowspan="1">Iran/EM</td><td align="left" colspan="1" rowspan="1">Cross-sectional</td><td align="left" colspan="1" rowspan="1">37.69&#8201;&#177;&#8201;5.87</td><td align="left" colspan="1" rowspan="1">(82.2%)M/(17.8%)F</td><td align="left" colspan="1" rowspan="1">354</td><td align="left" colspan="1" rowspan="1">Methadone/tramadol/opium/cocaine/heroin</td><td align="left" colspan="1" rowspan="1">2014/ICU hospitalized</td><td align="left" colspan="1" rowspan="1">No</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">******</td></tr><tr><td align="left" colspan="1" rowspan="1">25</td><td align="left" colspan="1" rowspan="1">Kitchen<sup><xref ref-type="bibr" rid="CR39">3</xref><xref ref-type="bibr" rid="CR39">9</xref></sup></td><td align="left" colspan="1" rowspan="1">2021</td><td align="left" colspan="1" rowspan="1">Canada/America</td><td align="left" colspan="1" rowspan="1">Cross-sectional</td><td align="left" colspan="1" rowspan="1">44.7 mean (31&#8211;54)</td><td align="left" colspan="1" rowspan="1">(57.3%)M/(42.7%)F</td><td align="left" colspan="1" rowspan="1">3552</td><td align="left" colspan="1" rowspan="1">Opium/heroin/methadone/synthetic/semisynthetic</td><td align="left" colspan="1" rowspan="1">Jan 2010&#8211;Dec 2019/total hospitalized</td><td align="left" colspan="1" rowspan="1">No</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">Oral/inhalation/IV</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">******</td></tr><tr><td align="left" colspan="1" rowspan="1">26</td><td align="left" colspan="1" rowspan="1">Kourouni<sup><xref ref-type="bibr" rid="CR40">4</xref><xref ref-type="bibr" rid="CR40">0</xref></sup></td><td align="left" colspan="1" rowspan="1">2020</td><td align="left" colspan="1" rowspan="1">USA/America</td><td align="left" colspan="1" rowspan="1">Case series</td><td align="left" colspan="1" rowspan="1">41 (25&#8211;59)</td><td align="left" colspan="1" rowspan="1">(80%)M/(20%)F</td><td align="left" colspan="1" rowspan="1">30</td><td align="left" colspan="1" rowspan="1">Synthetic cannabinoid</td><td align="left" colspan="1" rowspan="1">2014&#8211;2016/ICU hospitalized</td><td align="left" colspan="1" rowspan="1">Cannabinoids/BDZ cocaine/opioid//methadone</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">Ingestion</td><td align="left" colspan="1" rowspan="1">Psychiatric illness/personality disorder</td><td align="left" colspan="1" rowspan="1">*****</td></tr><tr><td align="left" colspan="1" rowspan="1">27</td><td align="left" colspan="1" rowspan="1">Lam<sup><xref ref-type="bibr" rid="CR41">4</xref><xref ref-type="bibr" rid="CR41">1</xref></sup></td><td align="left" colspan="1" rowspan="1">2010</td><td align="left" colspan="1" rowspan="1">China/WP</td><td align="left" colspan="1" rowspan="1">Cross sectional</td><td align="left" colspan="1" rowspan="1">38 (30&#8211;49)</td><td align="left" colspan="1" rowspan="1">(45.7%)M/(54.3%)F</td><td align="left" colspan="1" rowspan="1">265</td><td align="left" colspan="1" rowspan="1">Alcohol BDZ/TCA</td><td align="left" colspan="1" rowspan="1">Jan 2000&#8211;May 2008/ICU hospitalized</td><td align="left" colspan="1" rowspan="1">No</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">Psychiatric disease/MDD</td><td align="left" colspan="1" rowspan="1">******</td></tr><tr><td align="left" colspan="1" rowspan="1">28</td><td align="left" colspan="1" rowspan="1">Lavergne<sup><xref ref-type="bibr" rid="CR12">12</xref></sup></td><td align="left" colspan="1" rowspan="1">2016</td><td align="left" colspan="1" rowspan="1">USA/America</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">43.7 mean (43.7&#8211;44.9)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1745</td><td align="left" colspan="1" rowspan="1">Ethanol/methanol/cocaine/methadone</td><td align="left" colspan="1" rowspan="1">1993&#8211;2014/total hospitalized</td><td align="left" colspan="1" rowspan="1">No</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">******</td></tr><tr><td align="left" colspan="1" rowspan="1">29</td><td align="left" colspan="1" rowspan="1">Lund<sup><xref ref-type="bibr" rid="CR42">42</xref></sup></td><td align="left" colspan="1" rowspan="1">2012</td><td align="left" colspan="1" rowspan="1">Norway/Europe</td><td align="left" colspan="1" rowspan="1">Cross sectional</td><td align="left" colspan="1" rowspan="1">36 (16&#8211;93)</td><td align="left" colspan="1" rowspan="1">(55.5%)M/(44.5%)F</td><td align="left" colspan="1" rowspan="1">1065</td><td align="left" colspan="1" rowspan="1">Ethanol/opioids/cocaine/AMPH/BDZ</td><td align="left" colspan="1" rowspan="1">Apr 2008&#8211;Apr 14, 2009/total hospitalized</td><td align="left" colspan="1" rowspan="1">BDZ/paracetamol/ethanol/anabolic steroids</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">******</td></tr><tr><td align="left" colspan="1" rowspan="1">30</td><td align="left" colspan="1" rowspan="1">Mehrpour<sup><xref ref-type="bibr" rid="CR43">4</xref><xref ref-type="bibr" rid="CR43">3</xref></sup></td><td align="left" colspan="1" rowspan="1">2020</td><td align="left" colspan="1" rowspan="1">USA/America</td><td align="left" colspan="1" rowspan="1">Retrospective toxic registry</td><td align="left" colspan="1" rowspan="1">41.9&#8201;&#177;&#8201;16.6</td><td align="left" colspan="1" rowspan="1">(60.2%)M/(39.8%)F</td><td align="left" colspan="1" rowspan="1">973</td><td align="left" colspan="1" rowspan="1">Methadone</td><td align="left" colspan="1" rowspan="1">Jan 2010&#8211;Dec 2017/total hospitalized</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">111.34&#8201;&#177;&#8201;121.78 (mg)</td><td align="left" colspan="1" rowspan="1">Oral/parenteral</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">*******</td></tr><tr><td align="left" colspan="1" rowspan="1">31</td><td align="left" colspan="1" rowspan="1">Melli<sup><xref ref-type="bibr" rid="CR44">44</xref></sup></td><td align="left" colspan="1" rowspan="1">2005</td><td align="left" colspan="1" rowspan="1">USA/America</td><td align="left" colspan="1" rowspan="1">Prospective</td><td align="left" colspan="1" rowspan="1">47 median (4&#8211;95)</td><td align="left" colspan="1" rowspan="1">(68.2%)M/(31.8%)F</td><td align="left" colspan="1" rowspan="1">475</td><td align="left" colspan="1" rowspan="1">Illicit drugs/alcohol</td><td align="left" colspan="1" rowspan="1">Jan 1993&#8211;Dec 2001/total hospitalized</td><td align="left" colspan="1" rowspan="1">No</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">No</td><td align="left" colspan="1" rowspan="1">******</td></tr><tr><td align="left" colspan="1" rowspan="1">32</td><td align="left" colspan="1" rowspan="1">Monte<sup><xref ref-type="bibr" rid="CR45">45</xref></sup></td><td align="left" colspan="1" rowspan="1">2017</td><td align="left" colspan="1" rowspan="1">USA/America</td><td align="left" colspan="1" rowspan="1">Prospective</td><td align="left" colspan="1" rowspan="1">25 median (18&#8211;36)</td><td align="left" colspan="1" rowspan="1">(84.1%)M/(15.9%)F</td><td align="left" colspan="1" rowspan="1">353</td><td align="left" colspan="1" rowspan="1">Synthetic cannabinoids</td><td align="left" colspan="1" rowspan="1">Jan 2010&#8211;Jul 2015/total hospitalized</td><td align="left" colspan="1" rowspan="1">Marijuana/sympathomimetic</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">Inhalation</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">******</td></tr><tr><td align="left" colspan="1" rowspan="1">33</td><td align="left" colspan="1" rowspan="1">Mozafari<sup><xref ref-type="bibr" rid="CR46">46</xref></sup></td><td align="left" colspan="1" rowspan="1">2016</td><td align="left" colspan="1" rowspan="1">Iran/EM</td><td align="left" colspan="1" rowspan="1">Cross sectional</td><td align="left" colspan="1" rowspan="1">32.65&#8201;&#177;&#8201;14.4</td><td align="left" colspan="1" rowspan="1">(59%)M/(41%)F</td><td align="left" colspan="1" rowspan="1">310</td><td align="left" colspan="1" rowspan="1">AMPH/opium/methanol/tramadol/methadone</td><td align="left" colspan="1" rowspan="1">Feb 2014&#8211;Feb 2015/ICU hospitalized</td><td align="left" colspan="1" rowspan="1">No</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">No</td><td align="left" colspan="1" rowspan="1">*******</td></tr><tr><td align="left" colspan="1" rowspan="1">34</td><td align="left" colspan="1" rowspan="1">Morrow<sup><xref ref-type="bibr" rid="CR47">47</xref></sup></td><td align="left" colspan="1" rowspan="1">2019</td><td align="left" colspan="1" rowspan="1">Canada/America</td><td align="left" colspan="1" rowspan="1">Retrospective cohort</td><td align="left" colspan="1" rowspan="1">48 median (32&#8211;61)</td><td align="left" colspan="1" rowspan="1">(53.5%)M/(46.5%)F</td><td align="left" colspan="1" rowspan="1">2554</td><td align="left" colspan="1" rowspan="1">Opium/heroin/methadone/other opioids</td><td align="left" colspan="1" rowspan="1">2006 to 2015/total hospitalized</td><td align="left" colspan="1" rowspan="1">No</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">Psychiatric /Pneumonia/HIV/cancer</td><td align="left" colspan="1" rowspan="1">*******</td></tr><tr><td align="left" colspan="1" rowspan="1">35</td><td align="left" colspan="1" rowspan="1">Ng<sup><xref ref-type="bibr" rid="CR48">48</xref></sup></td><td align="left" colspan="1" rowspan="1">2019</td><td align="left" colspan="1" rowspan="1">Hong Kong/WP</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">36.5 median (27.5&#8211;53.2)</td><td align="left" colspan="1" rowspan="1">(56.3%)M/(43.7%)F</td><td align="left" colspan="1" rowspan="1">270</td><td align="left" colspan="1" rowspan="1">Ethanol/heroin/cocaine/AMPH/cannabis/tramadol</td><td align="left" colspan="1" rowspan="1">Jan 2007&#8211;Dec 2016/ICU hospitalized</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">Oral/inhalation/parenteral/insufflation</td><td align="left" colspan="1" rowspan="1">Psychiatric/schizophrenia,</td><td align="left" colspan="1" rowspan="1">*****</td></tr><tr><td align="left" colspan="1" rowspan="1">36</td><td align="left" colspan="1" rowspan="1">Nicol<sup><xref ref-type="bibr" rid="CR49">4</xref><xref ref-type="bibr" rid="CR49">9</xref></sup></td><td align="left" colspan="1" rowspan="1">2015</td><td align="left" colspan="1" rowspan="1">Canada/America</td><td align="left" colspan="1" rowspan="1">Retrospective case series</td><td align="left" colspan="1" rowspan="1">24 median (14&#8211;52)</td><td align="left" colspan="1" rowspan="1">(81.5%)M/(18.5%)F</td><td align="left" colspan="1" rowspan="1">27</td><td align="left" colspan="1" rowspan="1">PMA/MDMA</td><td align="left" colspan="1" rowspan="1">Jun 2011&#8211;Apr 2012/total hospitalized</td><td align="left" colspan="1" rowspan="1">AMPH/cocaine/MAMP</td><td align="left" colspan="1" rowspan="1">2.70&#8201;&#177;&#8201;1.72 (mg/l)</td><td align="left" colspan="1" rowspan="1">Oral</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">****</td></tr><tr><td align="left" colspan="1" rowspan="1">37</td><td align="left" colspan="1" rowspan="1">O&#8217;Connor<sup><xref ref-type="bibr" rid="CR50">5</xref><xref ref-type="bibr" rid="CR50">0</xref></sup></td><td align="left" colspan="1" rowspan="1">2015</td><td align="left" colspan="1" rowspan="1">USA/America</td><td align="left" colspan="1" rowspan="1">Retrospective chart review</td><td align="left" colspan="1" rowspan="1">32 median (25&#8211;42)</td><td align="left" colspan="1" rowspan="1">(74%)M/(26%)F</td><td align="left" colspan="1" rowspan="1">89</td><td align="left" colspan="1" rowspan="1">Synthetic cathinone&#8217;s/MAMP/cocaine</td><td align="left" colspan="1" rowspan="1">Jan 2010&#8211;Jan 2013/total hospitalized</td><td align="left" colspan="1" rowspan="1">No</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">Ingestion</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">********</td></tr><tr><td align="left" colspan="1" rowspan="1">38</td><td align="left" colspan="1" rowspan="1">Oladunjoye<sup><xref ref-type="bibr" rid="CR51">5</xref><xref ref-type="bibr" rid="CR51">1</xref></sup></td><td align="left" colspan="1" rowspan="1">2020</td><td align="left" colspan="1" rowspan="1">USA/America</td><td align="left" colspan="1" rowspan="1">Cross sectional</td><td align="left" colspan="1" rowspan="1">44.6&#8201;&#177;&#8201;0.1</td><td align="left" colspan="1" rowspan="1">(55%)M/(45%)F</td><td align="left" colspan="1" rowspan="1">2,528,751</td><td align="left" colspan="1" rowspan="1">Opium/heroin/methadone</td><td align="left" colspan="1" rowspan="1">Jan 2010&#8211;Dec 2014/total hospitalized</td><td align="left" colspan="1" rowspan="1">No</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">Hepatitis C</td><td align="left" colspan="1" rowspan="1">*******</td></tr><tr><td align="left" colspan="1" rowspan="1">39</td><td align="left" colspan="1" rowspan="1">Pajoumand<sup><xref ref-type="bibr" rid="CR52">5</xref><xref ref-type="bibr" rid="CR52">2</xref></sup></td><td align="left" colspan="1" rowspan="1">2018</td><td align="left" colspan="1" rowspan="1">Iran/EM</td><td align="left" colspan="1" rowspan="1">Retrospective cross-sectional</td><td align="left" colspan="1" rowspan="1">34.9&#8201;&#177;&#8201;14.5</td><td align="left" colspan="1" rowspan="1">(77%)M/(23%)F</td><td align="left" colspan="1" rowspan="1">315</td><td align="left" colspan="1" rowspan="1">Alcohol/opium</td><td align="left" colspan="1" rowspan="1">Jul 2011 and Jul 2017/total hospitalized</td><td align="left" colspan="1" rowspan="1">No</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">No</td><td align="left" colspan="1" rowspan="1">******</td></tr><tr><td align="left" colspan="1" rowspan="1">40</td><td align="left" colspan="1" rowspan="1">Rahimi<sup><xref ref-type="bibr" rid="CR53">53</xref></sup></td><td align="left" colspan="1" rowspan="1">2018</td><td align="left" colspan="1" rowspan="1">Iran/EM</td><td align="left" colspan="1" rowspan="1">Retrospective cross-sectional</td><td align="left" colspan="1" rowspan="1">32.9&#8201;&#177;&#8201;10.9</td><td align="left" colspan="1" rowspan="1">(77%)M/(23%)F</td><td align="left" colspan="1" rowspan="1">226</td><td align="left" colspan="1" rowspan="1">AMPH</td><td align="left" colspan="1" rowspan="1">Apr 2011&#8211;Mar 2014/total hospitalized</td><td align="left" colspan="1" rowspan="1">No</td><td align="left" colspan="1" rowspan="1">1.64&#8201;&#177;&#8201;1.59(gram)</td><td align="left" colspan="1" rowspan="1">Oral/inhalation/ injection</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">*******</td></tr><tr><td align="left" colspan="1" rowspan="1">41</td><td align="left" colspan="1" rowspan="1">Rahimi<sup><xref ref-type="bibr" rid="CR54">5</xref><xref ref-type="bibr" rid="CR54">4</xref></sup></td><td align="left" colspan="1" rowspan="1">2022</td><td align="left" colspan="1" rowspan="1">Iran/EM</td><td align="left" colspan="1" rowspan="1">Prospective</td><td align="left" colspan="1" rowspan="1">33 median (25, 49)</td><td align="left" colspan="1" rowspan="1">(92.7%)M/(7.3%)F</td><td align="left" colspan="1" rowspan="1">165</td><td align="left" colspan="1" rowspan="1">Opium/heroin/methadone/tramadol</td><td align="left" colspan="1" rowspan="1">Sep 2019&#8211;Mar 2020/ICU hospitalized</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">Oral/inhalation</td><td align="left" colspan="1" rowspan="1">DM/COPD/CHF/CVD/seizure</td><td align="left" colspan="1" rowspan="1">******</td></tr><tr><td align="left" colspan="1" rowspan="1">42</td><td align="left" colspan="1" rowspan="1">Richards<sup><xref ref-type="bibr" rid="CR9">9</xref></sup></td><td align="left" colspan="1" rowspan="1">2020</td><td align="left" colspan="1" rowspan="1">USA/America</td><td align="left" colspan="1" rowspan="1">Retrospective review</td><td align="left" colspan="1" rowspan="1">46&#8201;&#177;&#8201;15</td><td align="left" colspan="1" rowspan="1">(69%)M/(31%)F</td><td align="left" colspan="1" rowspan="1">215</td><td align="left" colspan="1" rowspan="1">Cocaine</td><td align="left" colspan="1" rowspan="1">Jul 2012&#8211;Jul 2017/total hospitalized</td><td align="left" colspan="1" rowspan="1">AMPH ethanol</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">CVD/psychiatric/neurological/GI/GU</td><td align="left" colspan="1" rowspan="1">********</td></tr><tr><td align="left" colspan="1" rowspan="1">43</td><td align="left" colspan="1" rowspan="1">Richards<sup><xref ref-type="bibr" rid="CR55">55</xref></sup></td><td align="left" colspan="1" rowspan="1">2020</td><td align="left" colspan="1" rowspan="1">USA/America</td><td align="left" colspan="1" rowspan="1">Retrospective review</td><td align="left" colspan="1" rowspan="1">Median 43&#8201;&#177;&#8201;13</td><td align="left" colspan="1" rowspan="1">(71%)M/(29%)F</td><td align="left" colspan="1" rowspan="1">957</td><td align="left" colspan="1" rowspan="1">MAMP AMPH</td><td align="left" colspan="1" rowspan="1">Jul 2012&#8211;Jul 2017/total hospitalized</td><td align="left" colspan="1" rowspan="1">Cocaine ethanol</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">Psychiatric/endocrine/GI/GU/ neurological</td><td align="left" colspan="1" rowspan="1">********</td></tr><tr><td align="left" colspan="1" rowspan="1">44</td><td align="left" colspan="1" rowspan="1">Riederer<sup><xref ref-type="bibr" rid="CR56">56</xref></sup></td><td align="left" colspan="1" rowspan="1">2017</td><td align="left" colspan="1" rowspan="1">USA/America</td><td align="left" colspan="1" rowspan="1">Case reports</td><td align="left" colspan="1" rowspan="1"><p>70.6 (19&#8211;65)</p><p>27.4 (13&#8211;18)</p></td><td align="left" colspan="1" rowspan="1">(83.1%)M/(16.9%)F</td><td align="left" colspan="1" rowspan="1">456</td><td align="left" colspan="1" rowspan="1">Synthetic cannabinoids</td><td align="left" colspan="1" rowspan="1">Jan 2010&#8211;Nov 2015/total hospitalized</td><td align="left" colspan="1" rowspan="1">No</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">*******</td></tr><tr><td align="left" colspan="1" rowspan="1">45</td><td align="left" colspan="1" rowspan="1">Ridpath<sup><xref ref-type="bibr" rid="CR57">57</xref></sup></td><td align="left" colspan="1" rowspan="1">2014</td><td align="left" colspan="1" rowspan="1">USA/America</td><td align="left" colspan="1" rowspan="1">Case report</td><td align="left" colspan="1" rowspan="1">21 median (16&#8211;29)</td><td align="left" colspan="1" rowspan="1">(41%)M/(59%)F</td><td align="left" colspan="1" rowspan="1">22</td><td align="left" colspan="1" rowspan="1">Alcohol/cocaine/ MDMA</td><td align="left" colspan="1" rowspan="1">Sep 2013 over the 3-day/total hospitalized</td><td align="left" colspan="1" rowspan="1">Synthetic club drug/marijuana/other drugs</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">*****</td></tr><tr><td align="left" colspan="1" rowspan="1">46</td><td align="left" colspan="1" rowspan="1">Sheibani<sup><xref ref-type="bibr" rid="CR11">11</xref></sup></td><td align="left" colspan="1" rowspan="1">2021</td><td align="left" colspan="1" rowspan="1">Iran/EM</td><td align="left" colspan="1" rowspan="1">Observational</td><td align="left" colspan="1" rowspan="1">33 (24&#8211;46) 63 (38&#8211;71)</td><td align="left" colspan="1" rowspan="1">(75.9%)M/(24.1%)F</td><td align="left" colspan="1" rowspan="1">245</td><td align="left" colspan="1" rowspan="1">Methadone</td><td align="left" colspan="1" rowspan="1">Jun 2018&#8211;Feb 2019/ICU hospitalized</td><td align="left" colspan="1" rowspan="1">No</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">Oral</td><td align="left" colspan="1" rowspan="1">No</td><td align="left" colspan="1" rowspan="1">******</td></tr><tr><td align="left" colspan="1" rowspan="1">47</td><td align="left" colspan="1" rowspan="1">Sporer<sup><xref ref-type="bibr" rid="CR58">5</xref><xref ref-type="bibr" rid="CR58">8</xref></sup></td><td align="left" colspan="1" rowspan="1">2001</td><td align="left" colspan="1" rowspan="1">USA/America</td><td align="left" colspan="1" rowspan="1">Retrospective chart review</td><td align="left" colspan="1" rowspan="1">34</td><td align="left" colspan="1" rowspan="1">(85.2%)M/(14.8%)F</td><td align="left" colspan="1" rowspan="1">27</td><td align="left" colspan="1" rowspan="1">Heroin</td><td align="left" colspan="1" rowspan="1">Aug 1994&#8211;Dec 1998/total hospitalized</td><td align="left" colspan="1" rowspan="1">No</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">*****</td></tr><tr><td align="left" colspan="1" rowspan="1">48</td><td align="left" colspan="1" rowspan="1">Taheri<sup><xref ref-type="bibr" rid="CR59">59</xref></sup></td><td align="left" colspan="1" rowspan="1">2013</td><td align="left" colspan="1" rowspan="1">Iran/EM</td><td align="left" colspan="1" rowspan="1">Cross-sectional</td><td align="left" colspan="1" rowspan="1">36.2&#8201;&#177;&#8201;14.50</td><td align="left" colspan="1" rowspan="1">(91.5%)M/(8.5%)F</td><td align="left" colspan="1" rowspan="1">82</td><td align="left" colspan="1" rowspan="1">Alcohol/narcotic/psychotropic</td><td align="left" colspan="1" rowspan="1">During a 6-month period in 2012/total hospitalized</td><td align="left" colspan="1" rowspan="1">No</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">******</td></tr><tr><td align="left" colspan="1" rowspan="1">49</td><td align="left" colspan="1" rowspan="1">Talaie<sup><xref ref-type="bibr" rid="CR8">8</xref></sup></td><td align="left" colspan="1" rowspan="1">2007</td><td align="left" colspan="1" rowspan="1">Iran/EM</td><td align="left" colspan="1" rowspan="1">Cross sectional</td><td align="left" colspan="1" rowspan="1">32.43&#8201;&#177;&#8201;14.31</td><td align="left" colspan="1" rowspan="1">(64.6%)M/(35.4%)F</td><td align="left" colspan="1" rowspan="1">181</td><td align="left" colspan="1" rowspan="1">Opium/alcohol/heroin</td><td align="left" colspan="1" rowspan="1">Sep 2004&#8211;Sep 2005/ICU hospitalized</td><td align="left" colspan="1" rowspan="1">BZD/TCA/carbamazepine/phenobarbital</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">No</td><td align="left" colspan="1" rowspan="1">******</td></tr><tr><td align="left" colspan="1" rowspan="1">50</td><td align="left" colspan="1" rowspan="1">Talaie<sup><xref ref-type="bibr" rid="CR60">6</xref><xref ref-type="bibr" rid="CR60">0</xref></sup></td><td align="left" colspan="1" rowspan="1">2019</td><td align="left" colspan="1" rowspan="1">Iran/EM</td><td align="left" colspan="1" rowspan="1">Cross-sectional</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">(71.8%)M/(28.2%)F</td><td align="left" colspan="1" rowspan="1">170</td><td align="left" colspan="1" rowspan="1">Opioid/methadone/stimulants</td><td align="left" colspan="1" rowspan="1">Jun 2015&#8211;Mar 2017/ICU hospitalized</td><td align="left" colspan="1" rowspan="1">Opioid/stimulants/TCA/CO</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">No</td><td align="left" colspan="1" rowspan="1">******</td></tr><tr><td align="left" colspan="1" rowspan="1">51</td><td align="left" colspan="1" rowspan="1">Talaie<sup><xref ref-type="bibr" rid="CR61">6</xref><xref ref-type="bibr" rid="CR61">1</xref></sup></td><td align="left" colspan="1" rowspan="1">2020</td><td align="left" colspan="1" rowspan="1">Iran/EM</td><td align="left" colspan="1" rowspan="1">Prospective/observational/cohort</td><td align="left" colspan="1" rowspan="1">39.43&#8201;&#177;&#8201;16.27</td><td align="left" colspan="1" rowspan="1">(67.4%)M/(32.6%)F</td><td align="left" colspan="1" rowspan="1">184</td><td align="left" colspan="1" rowspan="1">Methadone/tramadol/AMPH/opiate</td><td align="left" colspan="1" rowspan="1">Oct 2019&#8211;Aug 2020/ICU hospitalized</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">Neurological/CVA/psychiatric</td><td align="left" colspan="1" rowspan="1">*******</td></tr><tr><td align="left" colspan="1" rowspan="1">52</td><td align="left" colspan="1" rowspan="1">Tatusov<sup><xref ref-type="bibr" rid="CR62">6</xref><xref ref-type="bibr" rid="CR62">2</xref></sup></td><td align="left" colspan="1" rowspan="1">2019</td><td align="left" colspan="1" rowspan="1">USA/America</td><td align="left" colspan="1" rowspan="1">Retrospective case series</td><td align="left" colspan="1" rowspan="1">47 median (32&#8211;54)</td><td align="left" colspan="1" rowspan="1">(83%)M/(17%)F</td><td align="left" colspan="1" rowspan="1">23</td><td align="left" colspan="1" rowspan="1">Synthetic cannabinoids</td><td align="left" colspan="1" rowspan="1">Jan&#8211;Dec 2015/ICU hospitalized</td><td align="left" colspan="1" rowspan="1">Alcohol/BDZ/opioid/AMPH/cocaine/phencyclidine</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">*****</td></tr><tr><td align="left" colspan="1" rowspan="1">53</td><td align="left" colspan="1" rowspan="1">Thongprayoon<sup><xref ref-type="bibr" rid="CR4">4</xref></sup></td><td align="left" colspan="1" rowspan="1">2021</td><td align="left" colspan="1" rowspan="1">USA/America</td><td align="left" colspan="1" rowspan="1">Retrospective cohort</td><td align="left" colspan="1" rowspan="1">37.9&#8201;&#177;&#8201;18.3</td><td align="left" colspan="1" rowspan="1">(69.8%)M/(30.2%)F</td><td align="left" colspan="1" rowspan="1">603</td><td align="left" colspan="1" rowspan="1">Methanol</td><td align="left" colspan="1" rowspan="1">2003&#8211;2014/total hospitalized</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">oral</td><td align="left" colspan="1" rowspan="1">DM/HTN /anemia/CVA/CKD</td><td align="left" colspan="1" rowspan="1">*******</td></tr><tr><td align="left" colspan="1" rowspan="1">54</td><td align="left" colspan="1" rowspan="1">Waldman<sup><xref ref-type="bibr" rid="CR10">10</xref></sup></td><td align="left" colspan="1" rowspan="1">2021</td><td align="left" colspan="1" rowspan="1">10 countries/Europe</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">30 median (12&#8211;88)</td><td align="left" colspan="1" rowspan="1">(76.3%)M/(23.7%)F</td><td align="left" colspan="1" rowspan="1">1015</td><td align="left" colspan="1" rowspan="1">Cocaine/cannabis/AMPH/ heroin</td><td align="left" colspan="1" rowspan="1">Oct 2013&#8211;Sep 2014/total hospitalized</td><td align="left" colspan="1" rowspan="1">No</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">*******</td></tr><tr><td align="left" colspan="1" rowspan="1">55</td><td align="left" colspan="1" rowspan="1">Weng<sup><xref ref-type="bibr" rid="CR63">63</xref></sup></td><td align="left" colspan="1" rowspan="1">2022</td><td align="left" colspan="1" rowspan="1">Taiwan/WP</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">37 median (30&#8211;43.7)</td><td align="left" colspan="1" rowspan="1">(78.4%)M/(21.6%)F</td><td align="left" colspan="1" rowspan="1">379</td><td align="left" colspan="1" rowspan="1">MAMP</td><td align="left" colspan="1" rowspan="1">May 2017&#8211;Apr 2021/total hospitalized</td><td align="left" colspan="1" rowspan="1">No</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">Psychiatric/DM/HTN/cancer</td><td align="left" colspan="1" rowspan="1">******</td></tr><tr><td align="left" colspan="1" rowspan="1">56</td><td align="left" colspan="1" rowspan="1">West<sup><xref ref-type="bibr" rid="CR64">64</xref></sup></td><td align="left" colspan="1" rowspan="1">2010</td><td align="left" colspan="1" rowspan="1">USA/America</td><td align="left" colspan="1" rowspan="1">Observational case series</td><td align="left" colspan="1" rowspan="1">27 median (16&#8211;57)</td><td align="left" colspan="1" rowspan="1">(80%)M/(20%)F</td><td align="left" colspan="1" rowspan="1">55</td><td align="left" colspan="1" rowspan="1">MAMP</td><td align="left" colspan="1" rowspan="1">Jan 2001&#8211;Jul 2007/total hospitalized</td><td align="left" colspan="1" rowspan="1">Cannabinoids/BDZ/opiate/cocaine/BARB</td><td align="left" colspan="1" rowspan="1">Median 3.5 g</td><td align="left" colspan="1" rowspan="1">Oral/ingestion</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">*****</td></tr><tr><td align="left" colspan="1" rowspan="1">57</td><td align="left" colspan="1" rowspan="1">Yal&#231;&#305;n<sup><xref ref-type="bibr" rid="CR65">65</xref></sup></td><td align="left" colspan="1" rowspan="1">2019</td><td align="left" colspan="1" rowspan="1">Turkey/Europe</td><td align="left" colspan="1" rowspan="1">Retrospective</td><td align="left" colspan="1" rowspan="1">26.8&#8201;&#177;&#8201;7.5</td><td align="left" colspan="1" rowspan="1">(92.6%)M/(7.4%)F</td><td align="left" colspan="1" rowspan="1">340</td><td align="left" colspan="1" rowspan="1">Synthetic cannabinoids</td><td align="left" colspan="1" rowspan="1">Feb&#8211;May 2016/total hospitalized</td><td align="left" colspan="1" rowspan="1">Cannabis/alcohol</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">NA</td><td align="left" colspan="1" rowspan="1">Psychiatric illness</td><td align="left" colspan="1" rowspan="1">*******</td></tr></tbody></table><table-wrap-foot><p>*(Mean&#8201;&#177;&#8201;SD), Mean or Median (IQR).</p><p><italic toggle="yes">EM</italic> Eastern Mediterranean, <italic toggle="yes">WP</italic> Western Pacific, <italic toggle="yes">NA</italic> Not Available, <italic toggle="yes">IV</italic> Intravenous, <italic toggle="yes">PMH</italic> Past Medical History, <italic toggle="yes">PMA</italic> Paramethoxyamphetamine, <italic toggle="yes">BARB</italic> Barbiturate, <italic toggle="yes">AMPH</italic> Amphetamine, <italic toggle="yes">MAMP</italic> Methamphetamine, <italic toggle="yes">MDMA</italic> 3,4-methylenedioxyamphetamine, <italic toggle="yes">METH</italic> Methylamphetamine, <italic toggle="yes">THC</italic> Tetrahydrocannabinol, <italic toggle="yes">BDZ</italic> Benzodiazepines, <italic toggle="yes">LSD</italic> Lysergic acid diethylamide, <italic toggle="yes">GHB</italic> Gamma-Hydroxybutyrate, <italic toggle="yes">CO</italic> Carbon Monoxide, <italic toggle="yes">ADHD</italic> Attention-Deficit/Hyperactivity Disorder, <italic toggle="yes">CKD</italic> Chronic Kidney Disease, <italic toggle="yes">DM</italic> Diabetes Mellitus, <italic toggle="yes">COPD</italic> Chronic Obstructive Pulmonary Disease, <italic toggle="yes">CHF</italic> Congestive Heart Failure, <italic toggle="yes">CVD</italic> Cardiovascular Disease, <italic toggle="yes">HTN</italic> Hypertension, <italic toggle="yes">GI</italic> Gastrointestinal, <italic toggle="yes">GU</italic> Genitourinary.</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec11"><title>Pooled estimate of rhabdomyolysis occurrence</title><p id="Par14">The highest incidence of rhabdomyolysis occurrence was observed in heroin intoxication (57.2 [95% CI 22.6&#8211;91.8]), followed by amphetamines (30.5 [95% CI 22.6&#8211;38.5]) (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>), cocaine (26.6 [95% CI 11.1&#8211;42.1]), tramadol (17.07 [95% CI 10.6&#8211;23.5]), methadone (16.1 [95% CI 9.6&#8211;22.5]), synthetic cannabinoids (10.3 [95% CI 6.2&#8211;14.4]) (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>), and opioid (8.8 [95% CI 5.5&#8211;12.1]) (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>) (Table <xref rid="Tab3" ref-type="table">3</xref>). The pooled incidence of rhabdomyolysis was low for intoxication with methanol (2.0 [95% CI 0.5&#8211;3.5]) and ethanol (3.0 [95% CI 0.3&#8211;5.7]) when compared with other psychoactive substances. In the amphetamine family, the pooled estimate of rhabdomyolysis for methamphetamine was 40.3 (95% CI 23.6&#8211;57.04), for amphetamine was 26.9 (95% CI 12.2&#8211;41.5), and for ecstasy was 19.9 (95% CI 3.3&#8211;36.5).<fig id="Fig2" position="float" orientation="portrait"><label>Figure 2</label><caption><p>Pooled incidence of rhabdomyolysis based on the types of amphetamines intoxication.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="41598_2023_45031_Fig2_HTML.jpg"/></fig><fig id="Fig3" position="float" orientation="portrait"><label>Figure 3</label><caption><p>Pooled incidence of rhabdomyolysis for synthetic cannabinoid intoxication.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO3" position="float" orientation="portrait" xlink:href="41598_2023_45031_Fig3_HTML.jpg"/></fig><fig id="Fig4" position="float" orientation="portrait"><label>Figure 4</label><caption><p>Pooled incidence of rhabdomyolysis for opioid intoxication.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO4" position="float" orientation="portrait" xlink:href="41598_2023_45031_Fig4_HTML.jpg"/></fig><table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Overall and subgroup incidence of rhabdomyolysis according to psychoactive substances intoxication.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Drugs</th><th align="left" rowspan="2" colspan="1">Subgroup</th><th align="left" rowspan="2" colspan="1">Number of studies</th><th align="left" rowspan="2" colspan="1">Pooled ES (95%CI)</th><th align="left" colspan="2" rowspan="1">Heterogeneity</th><th align="left" rowspan="2" colspan="2"> Publication bias (p-value)</th></tr><tr><th align="left" colspan="1" rowspan="1">I<sup>2</sup> (%)</th><th align="left" colspan="1" rowspan="1">P-value</th></tr></thead><tbody><tr><td align="left" rowspan="12" colspan="1">Opioid</td><td align="left" colspan="1" rowspan="1">Total</td><td align="left" colspan="1" rowspan="1">11</td><td align="left" colspan="1" rowspan="1">8.8 (5.5&#8211;12.1)</td><td align="left" colspan="1" rowspan="1">99.9%</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">Begg&#8217;s</td><td align="left" colspan="1" rowspan="1">Egger&#8217;s</td></tr><tr><td align="left" colspan="5" rowspan="1">Subgroup analysis</td><td align="left" rowspan="11" colspan="1">0.76</td><td align="left" rowspan="11" colspan="1">0.49</td></tr><tr><td align="left" colspan="5" rowspan="1">Type of admission</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;ICU</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">13.6 (2&#8211;27.8)</td><td align="left" colspan="1" rowspan="1">91.0%</td><td align="left" colspan="1" rowspan="1">0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Total wards</td><td align="left" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">8.1 (4.3&#8211;11.8)</td><td align="left" colspan="1" rowspan="1">99.9%</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="5" rowspan="1">Multi-intoxication</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Yes</td><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">6.4 (3.1&#8211;10.6)</td><td align="left" colspan="1" rowspan="1">77.7%</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;No</td><td align="left" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">10.5 (4.8&#8211;17.9)</td><td align="left" colspan="1" rowspan="1">99.3%</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="5" rowspan="1">Geographic area</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;America</td><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">7.9 (3.2&#8211;14.4)</td><td align="left" colspan="1" rowspan="1">99.9%</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Eastern Mediterranean</td><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">11.4 (2.5&#8211;25.2)</td><td align="left" colspan="1" rowspan="1">29.7%</td><td align="left" colspan="1" rowspan="1">0.223</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;European</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">5.9 (2.8&#8211;9.9)</td><td align="left" colspan="1" rowspan="1">0.0%</td><td align="left" colspan="1" rowspan="1">0.861</td></tr><tr><td align="left" rowspan="11" colspan="1">Methadone</td><td align="left" colspan="1" rowspan="1">Total</td><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">16.1 (9.6&#8211;22.5)</td><td align="left" colspan="1" rowspan="1">93.4%</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td><td align="left" rowspan="11" colspan="1">0.042</td><td align="left" rowspan="11" colspan="1">0.020</td></tr><tr><td align="left" colspan="5" rowspan="1">Subgroup analysis</td></tr><tr><td align="left" colspan="5" rowspan="1">Type of admission</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;ICU</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">19.3 (1.6&#8211;37.0)</td><td align="left" colspan="1" rowspan="1">92.6%</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Total wards</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">16.5 (4.6&#8211;28.3)</td><td align="left" colspan="1" rowspan="1">95.9%</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="5" rowspan="1">Multi-intoxication</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Yes</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">4.4 (3.1&#8211;5.8)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;No</td><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">20.6 (10.3&#8211;30.8)</td><td align="left" colspan="1" rowspan="1">93.2%</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="5" rowspan="1">Geographic area</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;America</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">5.5 (4.2&#8211;7.1)</td><td align="left" colspan="1" rowspan="1">84.9%</td><td align="left" colspan="1" rowspan="1">0.01</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Eastern Mediterranean</td><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">16.6 (6.7&#8211;29.5)</td><td align="left" colspan="1" rowspan="1">38.5%</td><td align="left" colspan="1" rowspan="1">0.181</td></tr><tr><td align="left" rowspan="12" colspan="1">Synthetic cannabinoid</td><td align="left" colspan="1" rowspan="1">Total</td><td align="left" colspan="1" rowspan="1">11</td><td align="left" colspan="1" rowspan="1">10.3 (6.2&#8211;14.4)</td><td align="left" colspan="1" rowspan="1">90.5%</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td><td align="left" rowspan="12" colspan="1">0.073</td><td align="left" rowspan="12" colspan="1">0.015</td></tr><tr><td align="left" colspan="5" rowspan="1">Subgroup analysis</td></tr><tr><td align="left" colspan="5" rowspan="1">Type of admission</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;ICU</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">25.0 (9.0&#8211;41.1)</td><td align="left" colspan="1" rowspan="1">51.6%</td><td align="left" colspan="1" rowspan="1">0.13</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Total wards</td><td align="left" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">8.2 (4.2&#8211;12.3)</td><td align="left" colspan="1" rowspan="1">91.8%</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="5" rowspan="1">Multi-intoxication</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Yes</td><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">13.2 (6.5&#8211;21.7)</td><td align="left" colspan="1" rowspan="1">92.7%</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;No</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">6.1 (3.6&#8211;9.6)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="5" rowspan="1">Geographic area</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;America</td><td align="left" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">9.3 (3.7&#8211;16.6)</td><td align="left" colspan="1" rowspan="1">0.0%</td><td align="left" colspan="1" rowspan="1">0.568</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;European</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">30.7 (18.9&#8211;43.8)</td><td align="left" colspan="1" rowspan="1">0.0%</td><td align="left" colspan="1" rowspan="1">0.579</td></tr><tr><td align="left" colspan="1" rowspan="1">Western pacific</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">10.1 (7.6&#8211;12.9)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" rowspan="13" colspan="1">Amphetamines</td><td align="left" colspan="1" rowspan="1">Total</td><td align="left" colspan="1" rowspan="1">17</td><td align="left" colspan="1" rowspan="1">30.5 (22.6&#8211;38.5)</td><td align="left" colspan="1" rowspan="1">97.7%</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">Begg&#8217;s</td><td align="left" colspan="1" rowspan="1">Egger&#8217;s</td></tr><tr><td align="left" colspan="5" rowspan="1">Subgroup analysis</td><td align="left" rowspan="12" colspan="1">0.099</td><td align="left" rowspan="12" colspan="1">0.104</td></tr><tr><td align="left" colspan="5" rowspan="1">Type of admission</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;ICU</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">71.5 (12.8&#8211;100)</td><td align="left" colspan="1" rowspan="1">96.8%</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Total wards</td><td align="left" colspan="1" rowspan="1">14</td><td align="left" colspan="1" rowspan="1">22.7 (15.5&#8211;9.9)</td><td align="left" colspan="1" rowspan="1">97.1%</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="5" rowspan="1">Multi-intoxication</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Yes</td><td align="left" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">31.6 (16.8&#8211;48.4)</td><td align="left" colspan="1" rowspan="1">95.5%</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;No</td><td align="left" colspan="1" rowspan="1">9</td><td align="left" colspan="1" rowspan="1">24.1 (8.3&#8211;44.2)</td><td align="left" colspan="1" rowspan="1">97.1%</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="5" rowspan="1">Geographic area</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;America</td><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">65.6 (35.6&#8211;90.5)</td><td align="left" colspan="1" rowspan="1">79.7%</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Eastern Mediterranean</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">15.0 (3.2&#8211;37.8)</td><td align="left" colspan="1" rowspan="1">0.0%</td><td align="left" colspan="1" rowspan="1">0.541</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;European</td><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">16.3 (0.4&#8211;44.6)</td><td align="left" colspan="1" rowspan="1">78.3%</td><td align="left" colspan="1" rowspan="1">0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Western pacific</td><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">13.6 (4.5&#8211;26.3)</td><td align="left" colspan="1" rowspan="1">55.7%</td><td align="left" colspan="1" rowspan="1">0.079</td></tr><tr><td align="left" rowspan="11" colspan="1">Methanol</td><td align="left" colspan="1" rowspan="1">Total</td><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">2.0 (0.5&#8211;3.5)</td><td align="left" colspan="1" rowspan="1">74.0%</td><td align="left" colspan="1" rowspan="1">0.004</td><td align="left" rowspan="11" colspan="1">0.086</td><td align="left" rowspan="11" colspan="1">0.003</td></tr><tr><td align="left" colspan="5" rowspan="1">Subgroup analysis</td></tr><tr><td align="left" colspan="5" rowspan="1">Type of admission</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;ICU</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">21.0 (6.1&#8211;35.9)</td><td align="left" colspan="1" rowspan="1">0.0%</td><td align="left" colspan="1" rowspan="1">0.75</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Total wards</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">1.75 (0.5&#8211;2.4)</td><td align="left" colspan="1" rowspan="1">76.7%</td><td align="left" colspan="1" rowspan="1">0.014</td></tr><tr><td align="left" colspan="5" rowspan="1">Multi-intoxication</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Yes</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">2.3 (1.3&#8211;3.8)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;No</td><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">3.4 (0.2&#8211;8.9)</td><td align="left" colspan="1" rowspan="1">89.1%</td><td align="left" colspan="1" rowspan="1">0.001</td></tr><tr><td align="left" colspan="5" rowspan="1">Geographic area</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;America</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">1.6 (0.6&#8211;3.1)</td><td align="left" colspan="1" rowspan="1">0.0%</td><td align="left" colspan="1" rowspan="1">0.927</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Eastern Mediterranean</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">21.2 (8.2&#8211;37.4)</td><td align="left" colspan="1" rowspan="1">0.0%</td><td align="left" colspan="1" rowspan="1">0.889</td></tr><tr><td align="left" rowspan="9" colspan="1">Ethanol</td><td align="left" colspan="1" rowspan="1">Total</td><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">3.0 (0.3&#8211;5.7)</td><td align="left" colspan="1" rowspan="1">65.8%</td><td align="left" colspan="1" rowspan="1">0.03</td><td align="left" rowspan="9" colspan="1">0.497</td><td align="left" rowspan="9" colspan="1">0.305</td></tr><tr><td align="left" colspan="5" rowspan="1">Subgroup analysis</td></tr><tr><td align="left" colspan="5" rowspan="1">Multi-intoxication</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Yes</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">1.6 (0.5&#8211;3.2)</td><td align="left" colspan="1" rowspan="1">0.0%</td><td align="left" colspan="1" rowspan="1">0.42</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;No</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">2.5 (0.6&#8211;5.3)</td><td align="left" colspan="1" rowspan="1">55.7%</td><td align="left" colspan="1" rowspan="1">0.13</td></tr><tr><td align="left" colspan="5" rowspan="1">Geographic area</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;America</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">5.1 (2.9&#8211;8.1)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Eastern Mediterranean</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">33.3 (4.3&#8211;77.7)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;European</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">1.6 (0.5&#8211;3.2)</td><td align="left" colspan="1" rowspan="1">89.2%</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" rowspan="12" colspan="1">Cocaine</td><td align="left" colspan="1" rowspan="1">Total</td><td align="left" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">26.6 (11.1&#8211;42.1)</td><td align="left" colspan="1" rowspan="1">95.3%</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">Begg&#8217;s</td><td align="left" colspan="1" rowspan="1">Egger&#8217;s</td></tr><tr><td align="left" colspan="5" rowspan="1">Subgroup analysis</td><td align="left" rowspan="11" colspan="1">0.881</td><td align="left" rowspan="11" colspan="1">0.614</td></tr><tr><td align="left" colspan="5" rowspan="1">Type of admission</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;ICU</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">40.0 (0.5&#8211;79.5)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Total wards</td><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">25.4 (9.1&#8211;41.7)</td><td align="left" colspan="1" rowspan="1">96.1%</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="5" rowspan="1">Multi-intoxication</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Yes</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">23.2 (17.6&#8211;29.1)</td><td align="left" colspan="1" rowspan="1">0.0%</td><td align="left" colspan="1" rowspan="1">0.535</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;No</td><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">28.6 (9.3&#8211;52.5)</td><td align="left" colspan="1" rowspan="1">69.3%</td><td align="left" colspan="1" rowspan="1">0.01</td></tr><tr><td align="left" colspan="5" rowspan="1">Geographic area</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;America</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">29.9 (21.0&#8211;39.6)</td><td align="left" colspan="1" rowspan="1">0.0%</td><td align="left" colspan="1" rowspan="1">0.573</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;European</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">17.3 (0.05&#8211;56.6)</td><td align="left" colspan="1" rowspan="1">85.5%</td><td align="left" colspan="1" rowspan="1">0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Eastern Mediterranean</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">40.0 (5.27&#8211;85.3)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" rowspan="9" colspan="1">Heroin</td><td align="left" colspan="1" rowspan="1">Total</td><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">57.2 (22.6&#8211;91.8)</td><td align="left" colspan="1" rowspan="1">94.6%</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td><td align="left" rowspan="9" colspan="1">0.174</td><td align="left" rowspan="9" colspan="1">0.785</td></tr><tr><td align="left" colspan="5" rowspan="1">Subgroup analysis</td></tr><tr><td align="left" colspan="5" rowspan="1">Type of admission</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;ICU</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">100.0 (39.7&#8211;100)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Total wards</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">40.6 (7.1&#8211;79.5)</td><td align="left" colspan="1" rowspan="1">90.4%</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="5" rowspan="1">Geographic area</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;America</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">7.4 (0.9&#8211;24.3)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Eastern Mediterranean</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">100 (39.7&#8211;100)</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;European</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">50.3 (41.5&#8211;59.2)</td><td align="left" colspan="1" rowspan="1">0.0%</td><td align="left" colspan="1" rowspan="1">0.391</td></tr><tr><td align="left" colspan="1" rowspan="1">Tramadol</td><td align="left" colspan="1" rowspan="1">Total</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">17.07 (10.6&#8211;23.5)</td><td align="left" colspan="1" rowspan="1">0.0%</td><td align="left" colspan="1" rowspan="1">0.61</td><td align="left" colspan="1" rowspan="1">0.317</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" rowspan="13" colspan="1">Multiple drug</td><td align="left" colspan="1" rowspan="1">Total</td><td align="left" colspan="1" rowspan="1">15</td><td align="left" colspan="1" rowspan="1">29.7 (19.8&#8211;39.5)</td><td align="left" colspan="1" rowspan="1">98.6%</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td><td align="left" rowspan="13" colspan="1">0.458</td><td align="left" rowspan="13" colspan="1">0.712</td></tr><tr><td align="left" colspan="5" rowspan="1">Subgroup analysis</td></tr><tr><td align="left" colspan="5" rowspan="1">Type of admission</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;ICU</td><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">30.5 (14.4&#8211;49.4)</td><td align="left" colspan="1" rowspan="1">98.1%</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Total wards</td><td align="left" colspan="1" rowspan="1">9</td><td align="left" colspan="1" rowspan="1">26.7 (14.6&#8211;40.9)</td><td align="left" colspan="1" rowspan="1">98.4%</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="5" rowspan="1">Multi-intoxication</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Yes</td><td align="left" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">25.3 (11.7&#8211;42.0)</td><td align="left" colspan="1" rowspan="1">98.3%</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;No</td><td align="left" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">31.6 (20.2&#8211;44.1)</td><td align="left" colspan="1" rowspan="1">97.1%</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="5" rowspan="1">Geographic area</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;America</td><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">30.4 (19.6&#8211;42.3)</td><td align="left" colspan="1" rowspan="1">0.0%</td><td align="left" colspan="1" rowspan="1">0.558</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Eastern Mediterranean</td><td align="left" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">34.4 (19.5&#8211;51.0)</td><td align="left" colspan="1" rowspan="1">92.5%</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;European</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">34.4 (31.8&#8211;37.1)</td><td align="left" colspan="1" rowspan="1">97.5%</td><td align="left" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Western pacific</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">16.5 (13.5&#8211;19.8)</td><td align="left" colspan="1" rowspan="1">54.2%</td><td align="left" colspan="1" rowspan="1">0.139</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec12"><title>Subgroup analysis</title><sec id="Sec13"><title>Hospitalization ward and multi-intoxication</title><p id="Par15">The pooled effect size in the subgroup of ICU patients was higher than in the total wards (Table <xref rid="Tab3" ref-type="table">3</xref>). Incidence of rhabdomyolysis in ICU patients and total wards was respectively 13.6% vs 8.1% for opioids, 19.3% vs 16.5% for methadone, 25% vs 8.2% for synthetic cannabinoids, 40.0% vs 25.4% for cocaine, 71.5% vs 22.7% for amphetamines, 21% vs 1.75% for methanol, 100% vs 40.6% for heroin, and 30.5% vs 26.7% for multiple drug poisoning. In addition, pooled effect size in the subgroup of total wards was influenced by the severity of intoxication, which was different in the included studies. In comparison with multi-intoxication subgroup, pooled effect size of rhabdomyolysis occurrence was high in mono-intoxication subgroup except for synthetic cannabinoids (6.1% vs 13.2%) and amphetamines (24.1% vs 31.6%).</p></sec><sec id="Sec14"><title>Geographic area</title><p id="Par16">As it was showed in Table <xref rid="Tab3" ref-type="table">3</xref>, according to the subgroup analysis based on the geographic area, the highest incidence of rhabdomyolysis occurrence was related to amphetamines in American region (65.6% [35.6&#8211;90.5]) and synthetic cannabinoids in European region (30.7% [18.9&#8211;43.8]), whereas the highest incidence of rhabdomyolysis occurrence in Eastern Mediterranean was related to other psychoactive substances. Subgrouping by geographic region reduced heterogeneity between studies.</p></sec><sec id="Sec15"><title>Pooled mean effect size of renal function indexes</title><p id="Par17">Table <xref rid="Tab4" ref-type="table">4</xref> shows the comparison of mean effect size of renal function indexes in patients with and without rhabdomyolysis. Accordingly, the value of BUN (WMD&#8201;=&#8201;8.78, p&#8201;=&#8201;0.002), Cr (WMD&#8201;=&#8201;0.44, p&#8201;&lt;&#8201;0.001), and CPK (WMD&#8201;=&#8201;2590.9, p&#8201;&lt;&#8201;0.001) was significantly high in patients with rhabdomyolysis compared to those patients without rhabdomyolysis.<table-wrap id="Tab4" position="float" orientation="portrait"><label>Table 4</label><caption><p>Weighted mean difference of renal indices according to rhabdomyolysis.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Renal function index</th><th align="left" rowspan="2" colspan="1">Number of studies</th><th align="left" rowspan="2" colspan="1">Weighted Mean Difference (%95)</th><th align="left" rowspan="2" colspan="1">p-value group</th><th align="left" colspan="2" rowspan="1">Heterogeneity test</th><th align="left" colspan="2" rowspan="1">Publication bias</th></tr><tr><th align="left" colspan="1" rowspan="1">I<sup>2</sup> (%)</th><th align="left" colspan="1" rowspan="1">p-value</th><th align="left" colspan="1" rowspan="1">Egger&#8217;s</th><th align="left" colspan="1" rowspan="1">Begg&#8217;s</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">BUN (mg/dl)</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">8.78 (7.87&#8211;9.69)</td><td char="." align="char" colspan="1" rowspan="1">0.002</td><td char="." align="char" colspan="1" rowspan="1">25.13</td><td char="." align="char" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.394</td><td char="." align="char" colspan="1" rowspan="1">0.117</td><td char="." align="char" colspan="1" rowspan="1">0.274</td></tr><tr><td align="left" colspan="1" rowspan="1">Cr (mg/dl)</td><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">0.44 (0.22&#8211;0.65)</td><td char="." align="char" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td><td char="." align="char" colspan="1" rowspan="1">97.81</td><td char="." align="char" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td><td char="." align="char" colspan="1" rowspan="1">0.738</td><td char="." align="char" colspan="1" rowspan="1">0.993</td></tr><tr><td align="left" colspan="1" rowspan="1">CPK (u/l)</td><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">2590.9 (1973.8&#8211;3208.1)</td><td char="." align="char" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td><td char="." align="char" colspan="1" rowspan="1">98.72</td><td char="." align="char" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td><td char="." align="char" colspan="1" rowspan="1">0.348</td><td char="." align="char" colspan="1" rowspan="1">0.497</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">BUN</italic> Blood Urea Nitrogen, <italic toggle="yes">Cr</italic> Creatinine, <italic toggle="yes">CPK</italic> Creatine Phosphokinase.</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec16"><title>Publication bias and sensitivity analysis</title><p id="Par18">Table <xref rid="Tab3" ref-type="table">3</xref> represent specified p-values related to the publication bias in each type of psychoactive substances with Begg&#8217;s and Egger&#8217;s test, indicating that there was no publication bias in most of the intoxications. Sensitivity analysis was performed for all tests applied for meta-analysis and the results showed that none of the pooled effect size was influenced by a single study.</p></sec></sec></sec><sec id="Sec17"><title>Discussion</title><p id="Par19">The current study was a systematic review and meta-analysis of clinical data related to the incidence of rhabdomyolysis among intoxicated patients with psychoactive substances. To the best of our knowledge, this was the first systematic review conducted on rhabdomyolysis occurrence in psychoactive substance intoxication. Our results showed that pooled effect size for all categories of psychoactive substances was high in the subgroup of ICU patients compared with total wards. Also, intoxication with heroin (~&#8201;100) and amphetamine (~&#8201;71.5) showed the highest effect size for occurrence of rhabdomyolysis in ICU patients. In a study in Iran on 227 poisoned patients with refined opium extract, the majority of them (75.8%) were male. However, it has been documented that females have higher mitochondrial mass in skeletal muscle with greater oxidative phosphorylative capacities and therefore have greater protection against rhabdomyolysis<sup><xref ref-type="bibr" rid="CR66">66</xref>,<xref ref-type="bibr" rid="CR67">67</xref></sup>.</p><p id="Par20">A broad range of neurological complications affecting both central nervous system (CNS) and peripheral nervous system (PNS) are encountered in heroin abusers<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>. CNS lesions include brain hypoxia and seizure, spongiform leukoencephalopathy, stroke, and myelopathy<sup><xref ref-type="bibr" rid="CR68">68</xref></sup> while PNS involvement commonly manifests as compressive neuropathy or focal rhabdomyolysis<sup><xref ref-type="bibr" rid="CR69">69</xref></sup>. The etiology of this acute PNS complication is unclear. Some studies found immunological causes in patients who developed rhabdomyolysis. Also, mechanical trauma is considered a potential mechanism of focal nerve injury and localized rhabdomyolysis in heroin abusers<sup><xref ref-type="bibr" rid="CR70">70</xref></sup>. The effect size of rhabdomyolysis in ICU patients with heroin intoxication (100 [95% CI 39.7&#8211;100]) was the highest in our study.</p><p id="Par21">The second highest effect size of rhabdomyolysis in ICU patients was observed in intoxication with amphetamines (71.5 [95% CI 12.8&#8211;100]). The etiology of amphetamine-induced rhabdomyolysis has traditionally been attributed to agitation and/or physical restrain with intense isometric muscle contraction. However, many patients who use amphetamines are not agitated or restrained but experience rhabdomyolysis. Some of the indirect mechanisms and cofactors are gender difference (males at higher risk), monoamine receptor polymorphisms, cocaine and sedative co-injection, seizure, sepsis, and hyperthermia<sup><xref ref-type="bibr" rid="CR55">55</xref></sup>. Hyperthermia is a major toxic reaction to amphetamines that can lead to rhabdomyolysis, hypotension, disseminated intravascular coagulation (DIC), and AKI. Hyperthermia occurs as a result of complex interactions between serotonin, dopamine, norepinephrine, and environmental conditions<sup><xref ref-type="bibr" rid="CR71">71</xref></sup>. In some studies that reported a high frequency of rhabdomyolysis, there are several potential explanations for poor clinical outcomes and rhabdomyolyses like hyperthermia, concertation of amphetamines, and prolonged hypoxia. Most of the severe morbidity and mortality in these cases can be attributed to hyperthermia effects<sup><xref ref-type="bibr" rid="CR71">71</xref></sup>.</p><p id="Par22">In this study we found a higher effect size for patients with mono-intoxication than those with multi-intoxication following use of psychoactive substances. In many studies, alcohol abuse has been identified as a main cause of rhabdomyolysis<sup><xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR38">38</xref></sup> and other studies regarding the etiology of rhabdomyolysis have reported opioid overdose as a significant contributing factor to rhabdomyolysis<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>. In this regard, Talaie et al. reported that opium poisoning is the most common cause of rhabdomyolysis (23.3%), followed by poisoning with benzodiazepines, phenobarbital, propranolol, aluminum phosphide, alcohol, and co-poisoning<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>. Also, Babak et al.in their study reported that rhabdomyolysis is mostly associated with methadone abuse, followed by opium abuse, and is more commonly correlated with poisoning in younger patients<sup><xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR38">38</xref></sup>.</p></sec><sec id="Sec18"><title>Limitations</title><p id="Par23">The final analysis in our study was substantially limited in the number and quality of studies available. Our review only included the published studies but we tried our best to contact researchers and obtain more information about their studies. Also, few studies in our review reported seizure induced by psychoactive intoxication that may contribute to rhabdomyolysis in intoxicated patients. The next limitation is that we had disparities in the distribution of intoxication severity in total wards subgroup affecting the effect size of the study. Furthermore, distribution of type of psychoactive substance in the subgroup of multiple poisoning was different between studies, which affects the effect size of each study. These limitations and lack of clarity in the studies caused high heterogeneity in our analysis. Another limitation of this study is that we searched only studies with English full text or at least English abstracts, and also subgroup analysis was not possible based on the dose and route of the substance used, blood levels of the drug, and other variables due to insufficient reported data in the studies. In addition, we did not perform any blinding process for all stages of study selection, quality assessment, and data extraction. Therefore, we propose running more comprehensive and original research in this regard to help make a better conclusion regarding the incidence of rhabdomyolysis in patients with psychoactive substance intoxication.</p></sec><sec id="Sec19"><title>Conclusion</title><p id="Par24">In conclusion, this systematic review and meta-analysis revealed high incidence of rhabdomyolysis occurrence in patients with heroin and amphetamine intoxication compared to other psychoactive substances. Clinicians should anticipate this complication, monitor for rhabdomyolysis particularly in the ICU, and institute appropriate treatment protocols early in the patient&#8217;s clinical course.</p></sec></body><back><fn-group><fn><p><bold>Publisher's note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author contributions</title><p>The authors&#8217; responsibilities were as follows S.S., E.K., A.A. and S.M. Conceptual design; A.A., S.E. literature search; A.A., B.T., J.G. and A.S. screened the studies and extracted the data; B.M., S.M. and E.K. assessed the risk of bias; M.Y. and A.A. analyzed the data; A.A., A.S., T.M., J.G. and S.M. drafted the manuscript; M.Y., S.S. and E.K. modified the final manuscript; and all authors: read and approved the final manuscript.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>All data generated or analyzed during this study are available from the corresponding author on reasonable request.</p></notes><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par25">The authors declare no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parrott</surname><given-names>AC</given-names></name></person-group><article-title>Mood fluctuation and psychobiological instability: The same core functions are disrupted by novel psychoactive substances and established recreational drugs</article-title><source>Brain Sci.</source><year>2018</year><volume>8</volume><issue>3</issue><fpage>43</fpage><pub-id pub-id-type="pmid">29533974</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/brainsci8030043</pub-id><pub-id pub-id-type="pmcid">PMC5870361</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shukla</surname><given-names>L</given-names></name><name name-style="western"><surname>Ghadigaonkar</surname><given-names>DS</given-names></name><name name-style="western"><surname>Murthy</surname><given-names>P</given-names></name></person-group><article-title>Poisoning with drugs of abuse: Identification and management</article-title><source>Indian J. Crit. Care Med.</source><year>2019</year><volume>23</volume><fpage>S296</fpage><pub-id pub-id-type="pmid">32021008</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5005/jp-journals-10071-23309</pub-id><pub-id pub-id-type="pmcid">PMC6996663</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fudin</surname><given-names>HR</given-names></name><name name-style="western"><surname>Babin</surname><given-names>JL</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>AL</given-names></name><name name-style="western"><surname>Ray</surname><given-names>SD</given-names></name></person-group><article-title>Side effects of drugs annual</article-title><source>Drugs</source><year>2017</year><volume>39</volume><fpage>31</fpage><lpage>55</lpage></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thongprayoon</surname><given-names>C</given-names></name><etal/></person-group><article-title>Acute kidney injury in hospitalized patients with methanol intoxication: National Inpatient Sample 2003&#8211;2014</article-title><source>Hosp. Pract.</source><year>2021</year><volume>49</volume><fpage>203</fpage><lpage>208</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/21548331.2021.1882239</pub-id><pub-id pub-id-type="pmid">33496631</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petejova</surname><given-names>N</given-names></name><name name-style="western"><surname>Martinek</surname><given-names>A</given-names></name></person-group><article-title>Acute kidney injury due to rhabdomyolysis and renal replacement therapy: A critical review</article-title><source>Crit. Care.</source><year>2014</year><volume>18</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/cc13897</pub-id><pub-id pub-id-type="pmcid">PMC4056317</pub-id><pub-id pub-id-type="pmid">25043142</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Torres</surname><given-names>PA</given-names></name><name name-style="western"><surname>Helmstetter</surname><given-names>JA</given-names></name><name name-style="western"><surname>Kaye</surname><given-names>AM</given-names></name><name name-style="western"><surname>Kaye</surname><given-names>AD</given-names></name></person-group><article-title>Rhabdomyolysis: Pathogenesis, diagnosis, and treatment</article-title><source>Ochsner J.</source><year>2015</year><volume>15</volume><fpage>58</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">25829882</pub-id><pub-id pub-id-type="pmcid">PMC4365849</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cervellin</surname><given-names>G</given-names></name><name name-style="western"><surname>Comelli</surname><given-names>I</given-names></name><name name-style="western"><surname>Lippi</surname><given-names>G</given-names></name></person-group><article-title>Rhabdomyolysis: Historical background, clinical, diagnostic and therapeutic features</article-title><source>Clin. Chem. Lab. Med.</source><year>2010</year><volume>48</volume><fpage>749</fpage><lpage>756</lpage><pub-id pub-id-type="pmid">20298139</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1515/CCLM.2010.151</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Talaie</surname><given-names>H</given-names></name><etal/></person-group><article-title>Rhabdomyolysis among acute human poisoning cases</article-title><source>Hum. Exp. Toxicol.</source><year>2007</year><volume>26</volume><fpage>557</fpage><lpage>561</lpage><pub-id pub-id-type="pmid">17884958</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0960327107078667</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Richards</surname><given-names>JR</given-names></name><etal/></person-group><article-title>The association between cocaine use detected on drug screening and rhabdomyolysis</article-title><source>Toxicol. Commun.</source><year>2020</year><volume>4</volume><fpage>18</fpage><lpage>24</lpage></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Waldman</surname><given-names>W</given-names></name><etal/></person-group><article-title>Rhabdomyolysis related to acute recreational drug toxicity: A Euro-DEN study</article-title><source>PLoS ONE.</source><year>2021</year><volume>16</volume><fpage>e0246297</fpage><pub-id pub-id-type="pmid">33705425</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0246297</pub-id><pub-id pub-id-type="pmcid">PMC7951866</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sheibani</surname><given-names>M</given-names></name><etal/></person-group><article-title>Troponin, a predictor of mortality in methadone exposure: an observational prospective study</article-title><source>J. Am. Heart Assoc.</source><year>2021</year><volume>10</volume><fpage>e018899</fpage><pub-id pub-id-type="pmid">33821671</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/JAHA.120.018899</pub-id><pub-id pub-id-type="pmcid">PMC8174177</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lavergne</surname><given-names>V</given-names></name><name name-style="western"><surname>Hoffman</surname><given-names>RS</given-names></name><name name-style="western"><surname>Mowry</surname><given-names>JB</given-names></name><name name-style="western"><surname>Cormier</surname><given-names>M</given-names></name><name name-style="western"><surname>Gosselin</surname><given-names>S</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>DM</given-names></name><etal/></person-group><article-title>Why are we still dialyzing overdoses to tricyclic antidepressants? A subanalysis of the NPDS database</article-title><source>Semin. Dial.</source><year>2016</year><volume>1</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/sdi.12520</pub-id><pub-id pub-id-type="pmid">27490214</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Toews</surname><given-names>LC</given-names></name></person-group><article-title>Compliance of systematic reviews in veterinary journals with preferred reporting items for systematic reviews and meta-analysis (PRISMA) literature search reporting guidelines</article-title><source>J. Med. Libr. Assoc.</source><year>2017</year><volume>105</volume><fpage>233</fpage><pub-id pub-id-type="pmid">28670210</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5195/jmla.2017.246</pub-id><pub-id pub-id-type="pmcid">PMC5490700</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stahl</surname><given-names>K</given-names></name><name name-style="western"><surname>Rastelli</surname><given-names>E</given-names></name><name name-style="western"><surname>Schoser</surname><given-names>B</given-names></name></person-group><article-title>A systematic review on the definition of rhabdomyolysis</article-title><source>J. Neurol.</source><year>2020</year><volume>267</volume><fpage>877</fpage><lpage>882</lpage><pub-id pub-id-type="pmid">30617905</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00415-019-09185-4</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aghabiklooei</surname><given-names>A</given-names></name><name name-style="western"><surname>Edalatparvar</surname><given-names>M</given-names></name><name name-style="western"><surname>Zamani</surname><given-names>N</given-names></name><name name-style="western"><surname>Mostafazadeh</surname><given-names>B</given-names></name></person-group><article-title>Prognostic factors in acute methadone toxicity: A 5-year study</article-title><source>J. Toxicol.</source><year>2014</year><volume>2014</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2014/341826</pub-id><pub-id pub-id-type="pmcid">PMC4146352</pub-id><pub-id pub-id-type="pmid">25197273</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arefi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Renal failure prevalence in poisoned patients</article-title><source>Nephro-Urology.</source><year>2014</year><volume>6</volume><fpage>11910</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.5812/numonthly.11910</pub-id><pub-id pub-id-type="pmcid">PMC3997944</pub-id><pub-id pub-id-type="pmid">24783168</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Armenian</surname><given-names>P</given-names></name><etal/></person-group><article-title>Multiple MDMA (Ecstasy) overdoses at a rave event: A case series</article-title><source>J. Intens. Care Med.</source><year>2013</year><volume>28</volume><fpage>252</fpage><lpage>258</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0885066612445982</pub-id><pub-id pub-id-type="pmid">22640978</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Azarakhsh</surname><given-names>M</given-names></name><name name-style="western"><surname>Rahimi</surname><given-names>M</given-names></name><name name-style="western"><surname>Zamani</surname><given-names>N</given-names></name><name name-style="western"><surname>Arbabi</surname><given-names>S</given-names></name></person-group><article-title>Refined opium extract (shireh) poisoning: A 10-year retrospective study in a referral poison control centre in Iran</article-title><source>Asia Pac. J. Med. Toxicol.</source><year>2021</year><volume>10</volume><fpage>12</fpage><lpage>17</lpage></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brahmi</surname><given-names>N</given-names></name><etal/></person-group><article-title>Methanol poisoning in Tunisia: Report of 16 cases</article-title><source>Clin. Toxicol.</source><year>2007</year><volume>45</volume><fpage>717</fpage><lpage>720</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/15563650701502600</pub-id><pub-id pub-id-type="pmid">17849250</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="other">Bruggisser, M., Bodmer, M., Wilks, M., Kupferschmidt, H. &amp; Liechti, M. Retrospective analysis of stimulant abuse cases reported to the Swiss Toxicological Information Centre during 1997&#8211;2009. in <italic toggle="yes">Swiss medical weekly.</italic> (2010).<pub-id pub-id-type="doi" assigning-authority="pmc">10.4414/smw.2010.13115</pub-id><pub-id pub-id-type="pmid">21188679</pub-id></mixed-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burton</surname><given-names>BN</given-names></name><name name-style="western"><surname>Lin</surname><given-names>TC</given-names></name><name name-style="western"><surname>Said</surname><given-names>ET</given-names></name><name name-style="western"><surname>Gabriel</surname><given-names>RA</given-names></name></person-group><article-title>National trends and factors associated with inpatient mortality in adult patients with opioid overdose</article-title><source>Anesthes. Analg.</source><year>2019</year><volume>128</volume><fpage>152</fpage><lpage>160</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1213/ANE.0000000000003755</pub-id><pub-id pub-id-type="pmid">30198926</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caldicott</surname><given-names>DG</given-names></name><etal/></person-group><article-title>Dancing with &#8220;death&#8221;: p-Methoxyamphetamine overdose and its acute management</article-title><source>J. Toxicol. Clin. Toxicol.</source><year>2003</year><volume>41</volume><fpage>143</fpage><lpage>154</lpage><pub-id pub-id-type="pmid">12733852</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1081/clt-120019130</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chhabra</surname><given-names>N</given-names></name><name name-style="western"><surname>Gimbar</surname><given-names>RP</given-names></name><name name-style="western"><surname>Walla</surname><given-names>LM</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>TM</given-names></name></person-group><article-title>Emergency department patient burden from an electronic dance music festival</article-title><source>J. Emerg. Med.</source><year>2018</year><volume>54</volume><fpage>435</fpage><lpage>439</lpage><pub-id pub-id-type="pmid">29108735</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jemermed.2017.10.007</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dabby</surname><given-names>R</given-names></name><etal/></person-group><article-title>Acute heroin-related neuropathy</article-title><source>J. Periph. Nerv. Syst.</source><year>2006</year><volume>11</volume><fpage>304</fpage><lpage>309</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1529-8027.2006.00102.x</pub-id><pub-id pub-id-type="pmid">17117938</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Forrester</surname><given-names>MB</given-names></name><name name-style="western"><surname>Kleinschmidt</surname><given-names>K</given-names></name><name name-style="western"><surname>Schwarz</surname><given-names>E</given-names></name><name name-style="western"><surname>Young</surname><given-names>A</given-names></name></person-group><article-title>Synthetic cannabinoid exposures reported to Texas poison centers</article-title><source>J. Addict. Dis.</source><year>2011</year><volume>30</volume><fpage>351</fpage><lpage>358</lpage><pub-id pub-id-type="pmid">22026527</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/10550887.2011.609807</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gilley</surname><given-names>M</given-names></name><etal/></person-group><article-title>Synthetic cannabinoid exposure in adolescents presenting for emergency care</article-title><source>Pediatr. Emerg. Care.</source><year>2021</year><volume>37</volume><fpage>e13</fpage><lpage>e16</lpage><pub-id pub-id-type="pmid">29538266</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/PEC.0000000000001454</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Greene</surname><given-names>SL</given-names></name><name name-style="western"><surname>Dargan</surname><given-names>PI</given-names></name><name name-style="western"><surname>O'connor</surname><given-names>N</given-names></name><name name-style="western"><surname>Jones</surname><given-names>AL</given-names></name><name name-style="western"><surname>Kerins</surname><given-names>M</given-names></name></person-group><article-title>Multiple toxicity from 3, 4-methylenedioxymethamphetamine (&#8220;ecstasy&#8221;)</article-title><source>Am. J. Emerg. Med.</source><year>2003</year><volume>21</volume><fpage>121</fpage><lpage>124</lpage><pub-id pub-id-type="pmid">12671812</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/ajem.2003.50028</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Halpern</surname><given-names>P</given-names></name><etal/></person-group><article-title>Morbidity associated with MDMA (ecstasy) abuse: A survey of emergency department admissions</article-title><source>Hum. Exp. Toxicol.</source><year>2011</year><volume>30</volume><fpage>259</fpage><lpage>266</lpage><pub-id pub-id-type="pmid">20488845</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0960327110370984</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hermanns-Clausen</surname><given-names>M</given-names></name><name name-style="western"><surname>Kneisel</surname><given-names>S</given-names></name><name name-style="western"><surname>Szabo</surname><given-names>B</given-names></name><name name-style="western"><surname>Auw&#228;rter</surname><given-names>V</given-names></name></person-group><article-title>Acute toxicity due to the confirmed consumption of synthetic cannabinoids: Clinical and laboratory findings</article-title><source>Addiction.</source><year>2013</year><volume>108</volume><fpage>534</fpage><lpage>544</lpage><pub-id pub-id-type="pmid">22971158</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1360-0443.2012.04078.x</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heyerdahl</surname><given-names>F</given-names></name><etal/></person-group><article-title>Acute poisonings treated in hospitals in Oslo: A one-year prospective study (II): Clinical outcome</article-title><source>Clin. Toxicol.</source><year>2008</year><volume>46</volume><fpage>42</fpage><lpage>49</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/15563650701210048</pub-id><pub-id pub-id-type="pmid">18167036</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Imam</surname><given-names>SF</given-names></name><etal/></person-group><article-title>Bath salts intoxication: A case series</article-title><source>J. Emerg. Med.</source><year>2013</year><volume>45</volume><fpage>361</fpage><lpage>365</lpage><pub-id pub-id-type="pmid">23827164</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jemermed.2013.04.017</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Isoardi</surname><given-names>KZ</given-names></name><name name-style="western"><surname>Ayles</surname><given-names>SF</given-names></name><name name-style="western"><surname>Harris</surname><given-names>K</given-names></name><name name-style="western"><surname>Finch</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Page</surname><given-names>CB</given-names></name></person-group><article-title>Methamphetamine presentations to an emergency department: Management and complications</article-title><source>Emerg. Med. Austral.</source><year>2019</year><volume>31</volume><fpage>593</fpage><lpage>599</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/1742-6723.13219</pub-id><pub-id pub-id-type="pmid">30592564</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Isoardi</surname><given-names>KZ</given-names></name><name name-style="western"><surname>Mudge</surname><given-names>DW</given-names></name><name name-style="western"><surname>Harris</surname><given-names>K</given-names></name><name name-style="western"><surname>Dimeski</surname><given-names>G</given-names></name><name name-style="western"><surname>Buckley</surname><given-names>NA</given-names></name></person-group><article-title>Methamphetamine intoxication and acute kidney injury: A prospective observational case series</article-title><source>Nephrology.</source><year>2020</year><volume>25</volume><fpage>758</fpage><lpage>764</lpage><pub-id pub-id-type="pmid">32725693</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/nep.13762</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaewput</surname><given-names>W</given-names></name><etal/></person-group><article-title>Inpatient burden and mortality of methanol intoxication in the United States</article-title><source>Am. J. Med. Sci.</source><year>2021</year><volume>361</volume><fpage>69</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">32958166</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.amjms.2020.08.014</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kamijo</surname><given-names>Y</given-names></name><etal/></person-group><article-title>A multicenter retrospective survey of poisoning after consumption of products containing synthetic chemicals in Japan</article-title><source>Intern. Med.</source><year>2014</year><volume>53</volume><fpage>2439</fpage><lpage>2445</lpage><pub-id pub-id-type="pmid">25366001</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2169/internalmedicine.53.2344</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kasper</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Severe illness associated with reported use of synthetic cannabinoids: a public health investigation (Mississippi, 2015)</article-title><source>Clin. Toxicol.</source><year>2019</year><volume>57</volume><fpage>10</fpage><lpage>18</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/15563650.2018.1485927</pub-id><pub-id pub-id-type="pmcid">PMC11331360</pub-id><pub-id pub-id-type="pmid">29989463</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Katz</surname><given-names>KD</given-names></name><etal/></person-group><article-title>Case series of synthetic cannabinoid intoxication from one toxicology center</article-title><source>West. J. Emerg. Med.</source><year>2016</year><volume>17</volume><fpage>290</fpage><pub-id pub-id-type="pmid">27330661</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5811/westjem.2016.2.29519</pub-id><pub-id pub-id-type="pmcid">PMC4899060</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Babak</surname><given-names>K</given-names></name><name name-style="western"><surname>Mohammad</surname><given-names>A</given-names></name><name name-style="western"><surname>Mazaher</surname><given-names>G</given-names></name><name name-style="western"><surname>Samaneh</surname><given-names>A</given-names></name><name name-style="western"><surname>Fatemeh</surname><given-names>T</given-names></name></person-group><article-title>Clinical and laboratory findings of rhabdomyolysis in opioid overdose patients in the intensive care unit of a poisoning center in 2014 in Iran</article-title><source>Epidemiol. Health.</source><year>2017</year><volume>39</volume><fpage>4</fpage><pub-id pub-id-type="doi">10.4178/epih.e2017050</pub-id><pub-id pub-id-type="pmcid">PMC5790980</pub-id><pub-id pub-id-type="pmid">29121712</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kitchen</surname><given-names>SA</given-names></name><etal/></person-group><article-title>Trends and outcomes of serious complications associated with non-fatal opioid overdoses in Ontario, Canada</article-title><source>Drug Alcohol Depend.</source><year>2021</year><volume>225</volume><fpage>108830</fpage><pub-id pub-id-type="pmid">34182376</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drugalcdep.2021.108830</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kourouni</surname><given-names>I</given-names></name><name name-style="western"><surname>Mourad</surname><given-names>B</given-names></name><name name-style="western"><surname>Khouli</surname><given-names>H</given-names></name><name name-style="western"><surname>Shapiro</surname><given-names>JM</given-names></name><name name-style="western"><surname>Mathew</surname><given-names>JP</given-names></name></person-group><article-title>Critical illness secondary to synthetic cannabinoid ingestion</article-title><source>JAMA Netw. Open.</source><year>2020</year><volume>3</volume><fpage>e208516</fpage><lpage>e208516</lpage><pub-id pub-id-type="pmid">32687586</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2020.8516</pub-id><pub-id pub-id-type="pmcid">PMC7372325</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lam</surname><given-names>S-M</given-names></name><name name-style="western"><surname>Lau</surname><given-names>AC-W</given-names></name><name name-style="western"><surname>Yan</surname><given-names>W-W</given-names></name></person-group><article-title>Over 8 years experience on severe acute poisoning requiring intensive care in Hong Kong, China</article-title><source>Hum. Exp. Toxicol.</source><year>2010</year><volume>29</volume><fpage>757</fpage><lpage>765</lpage><pub-id pub-id-type="pmid">20144961</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0960327110361753</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lund</surname><given-names>C</given-names></name><etal/></person-group><article-title>A one-year observational study of all hospitalized acute poisonings in Oslo: Complications, treatment and sequelae</article-title><source>Scand. J. Trauma Resuscit. Emerg. Med.</source><year>2012</year><volume>20</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1757-7241-20-49</pub-id><pub-id pub-id-type="pmcid">PMC3413541</pub-id><pub-id pub-id-type="pmid">22828054</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mehrpour</surname><given-names>O</given-names></name><name name-style="western"><surname>Hoyte</surname><given-names>C</given-names></name><name name-style="western"><surname>Amirabadizadeh</surname><given-names>A</given-names></name><name name-style="western"><surname>Brent</surname><given-names>J</given-names></name></person-group><article-title>Clinical characteristics and time trends of hospitalized methadone exposures in the United States based on the Toxicology Investigators Consortium (ToxIC) case registry: 2010&#8211;2017</article-title><source>BMC Pharmacol. Toxicol.</source><year>2020</year><volume>21</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">32698849</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40360-020-00435-0</pub-id><pub-id pub-id-type="pmcid">PMC7376634</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Melli</surname><given-names>G</given-names></name><name name-style="western"><surname>Chaudhry</surname><given-names>V</given-names></name><name name-style="western"><surname>Cornblath</surname><given-names>DR</given-names></name></person-group><article-title>Rhabdomyolysis: an evaluation of 475 hospitalized patients</article-title><source>Medicine.</source><year>2005</year><volume>84</volume><fpage>377</fpage><lpage>385</lpage><pub-id pub-id-type="pmid">16267412</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/01.md.0000188565.48918.41</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Monte</surname><given-names>AA</given-names></name><etal/></person-group><article-title>Characteristics and treatment of patients with clinical illness due to synthetic cannabinoid inhalation reported by medical toxicologists: A ToxIC database study</article-title><source>J. Med. Toxicol.</source><year>2017</year><volume>13</volume><fpage>146</fpage><lpage>152</lpage><pub-id pub-id-type="pmid">28397128</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13181-017-0605-9</pub-id><pub-id pub-id-type="pmcid">PMC5440319</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mozafari</surname><given-names>N</given-names></name><name name-style="western"><surname>Talaie</surname><given-names>H</given-names></name><name name-style="western"><surname>Shoaei</surname><given-names>SD</given-names></name><name name-style="western"><surname>Hashemian</surname><given-names>M</given-names></name><name name-style="western"><surname>Mahdavinejad</surname><given-names>A</given-names></name></person-group><article-title>Survey on hypothermia and hyperthermia in poisoned patients in a unique referral hospital, Tehran, Iran</article-title><source>Iran. Red Crescent Med. J.</source><year>2016</year><volume>18</volume><fpage>483</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.5812/ircmj.35483</pub-id><pub-id pub-id-type="pmcid">PMC4893414</pub-id><pub-id pub-id-type="pmid">27275403</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morrow</surname><given-names>RL</given-names></name><name name-style="western"><surname>Bassett</surname><given-names>K</given-names></name><name name-style="western"><surname>Maclure</surname><given-names>M</given-names></name><name name-style="western"><surname>Dormuth</surname><given-names>CR</given-names></name></person-group><article-title>Outcomes associated with hospital admissions for accidental opioid overdose in British Columbia: A retrospective cohort study</article-title><source>BMJ Open.</source><year>2019</year><volume>9</volume><fpage>e025567</fpage><pub-id pub-id-type="pmid">31061028</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmjopen-2018-025567</pub-id><pub-id pub-id-type="pmcid">PMC6502019</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ng</surname><given-names>F</given-names></name></person-group><article-title>Ten-year profile of acute poisoning patients presenting to an accident and emergency department requiring intensive care in a regional hospital of Hong Kong</article-title><source>Hong Kong J. Emerg. Med.</source><year>2019</year><volume>26</volume><fpage>3</fpage><lpage>14</lpage></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nicol</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Deaths from exposure to paramethoxymethamphetamine in Alberta and British Columbia, Canada: A case series</article-title><source>Can. Med. Assoc. Open Access J.</source><year>2015</year><volume>3</volume><fpage>E83</fpage><lpage>E90</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.9778/cmajo.20140070</pub-id><pub-id pub-id-type="pmcid">PMC4382046</pub-id><pub-id pub-id-type="pmid">25844375</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Connor</surname><given-names>AD</given-names></name><name name-style="western"><surname>Padilla-Jones</surname><given-names>A</given-names></name><name name-style="western"><surname>Gerkin</surname><given-names>RD</given-names></name><name name-style="western"><surname>Levine</surname><given-names>M</given-names></name></person-group><article-title>Prevalence of rhabdomyolysis in sympathomimetic toxicity: A comparison of stimulants</article-title><source>J. Med. Toxicol.</source><year>2015</year><volume>11</volume><fpage>195</fpage><lpage>200</lpage><pub-id pub-id-type="pmid">25468315</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13181-014-0451-y</pub-id><pub-id pub-id-type="pmcid">PMC4469713</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oladunjoye</surname><given-names>AO</given-names></name><name name-style="western"><surname>Oladunjoye</surname><given-names>OO</given-names></name><name name-style="western"><surname>Olubiyi</surname><given-names>O</given-names></name><name name-style="western"><surname>Yee</surname><given-names>MR</given-names></name><name name-style="western"><surname>Espiridion</surname><given-names>ED</given-names></name></person-group><article-title>Predictors and outcomes of invasive mechanical ventilation in opioid overdose hospitalization in the United States</article-title><source>Cureus.</source><year>2020</year><volume>12</volume><fpage>9788</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.7759/cureus.9788</pub-id><pub-id pub-id-type="pmcid">PMC7491682</pub-id><pub-id pub-id-type="pmid">32953304</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pajoum</surname><given-names>A</given-names></name><etal/></person-group><article-title>Rhabdomyolysis and acute poisoning; a brief report</article-title><source>Emergency</source><year>2018</year><volume>6</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="pmcid">PMC6289148</pub-id><pub-id pub-id-type="pmid">30584572</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rahimi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Predictive factors of mortality in acute amphetamine type stimulants poisoning; a review of 226 cases</article-title><source>Emergency</source><year>2018</year><volume>6</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="pmcid">PMC5827041</pub-id><pub-id pub-id-type="pmid">29503826</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rahimi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Planned Versus unplanned extubation in opioid overdose patients: Does it have any effect on the prognosis? A cohort study</article-title><source>Iran. J. Toxicol.</source><year>2022</year><volume>16</volume><fpage>185</fpage><lpage>194</lpage></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Richards</surname><given-names>JR</given-names></name><etal/></person-group><article-title>Rhabdomyolysis, methamphetamine, amphetamine and MDMA Use: Associated factors and risks</article-title><source>J. Dual Diagn.</source><year>2020</year><volume>16</volume><fpage>429</fpage><lpage>437</lpage><pub-id pub-id-type="pmid">32644906</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/15504263.2020.1786617</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Riederer</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Acute poisonings from synthetic cannabinoids&#8212;50 US toxicology investigators consortium registry sites, 2010&#8211;2015</article-title><source>MMWR. Morbid. Mortal. Wkly. Rep.</source><year>2016</year><volume>65</volume><fpage>692</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.15585/mmwr.mm6527a2</pub-id><pub-id pub-id-type="pmcid">PMC4972329</pub-id><pub-id pub-id-type="pmid">27413997</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ridpath</surname><given-names>A</given-names></name><etal/></person-group><article-title>Illnesses and deaths among persons attending an electronic dance-music festival&#8212;New York City, 2013</article-title><source>MMWR. Morbid. Mortal. Wkly. Rep.</source><year>2014</year><volume>63</volume><fpage>1195</fpage><pub-id pub-id-type="pmcid">PMC5779530</pub-id><pub-id pub-id-type="pmid">25522087</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sporer</surname><given-names>KA</given-names></name><name name-style="western"><surname>Dorn</surname><given-names>E</given-names></name></person-group><article-title>Heroin-related noncardiogenic pulmonary edema: A case series</article-title><source>Chest</source><year>2001</year><volume>120</volume><fpage>1628</fpage><lpage>1632</lpage><pub-id pub-id-type="pmid">11713145</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1378/chest.120.5.1628</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taheri</surname><given-names>SK</given-names></name><name name-style="western"><surname>Afzali</surname><given-names>S</given-names></name><name name-style="western"><surname>Torabian</surname><given-names>S</given-names></name></person-group><article-title>Rhabdomyolysis syndrome in alcohol, psychotropic drugs, and illicit substance poisonings</article-title><source>Iran. J. Toxicol.</source><year>2013</year><volume>7</volume><fpage>866</fpage><lpage>870</lpage></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Talaie</surname><given-names>H</given-names></name><etal/></person-group><article-title>High sensitivity versus low level of vancomycin needs to be concern for another alternative anti-<italic toggle="yes">Staphylococcus aureus</italic> as the first-line antibiotic</article-title><source>Acta Bio Med. Atenei Parmensis</source><year>2019</year><volume>90</volume><fpage>498</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.23750/abm.v90i4.7646</pub-id><pub-id pub-id-type="pmcid">PMC7233789</pub-id><pub-id pub-id-type="pmid">31910175</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Talaie</surname><given-names>H</given-names></name><name name-style="western"><surname>Hosseini</surname><given-names>SM</given-names></name><name name-style="western"><surname>Nazari</surname><given-names>M</given-names></name><name name-style="western"><surname>Esfahani</surname><given-names>MS</given-names></name><name name-style="western"><surname>Barari</surname><given-names>B</given-names></name></person-group><article-title>Risk factors of hospital-acquired thrombocytopenia in toxicological intensive care unit</article-title><source>Int. J. Med. Toxicol. Forens. Med.</source><year>2020</year><volume>10</volume><fpage>32256</fpage><lpage>32256</lpage></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tatusov</surname><given-names>M</given-names></name><name name-style="western"><surname>Mazer-Amirshahi</surname><given-names>M</given-names></name><name name-style="western"><surname>Abbasi</surname><given-names>A</given-names></name><name name-style="western"><surname>Goyal</surname><given-names>M</given-names></name></person-group><article-title>Clinical effects of reported synthetic cannabinoid exposure in patients admitted to the intensive care unit</article-title><source>Am. J. Emerg. Med.</source><year>2019</year><volume>37</volume><fpage>1060</fpage><lpage>1064</lpage><pub-id pub-id-type="pmid">30146395</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajem.2018.08.048</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weng</surname><given-names>T-I</given-names></name><etal/></person-group><article-title>Comparison of clinical characteristics between meth/amphetamine and synthetic cathinone users presented to the emergency department</article-title><source>Clin.Toxicol.</source><year>2022</year><volume>1</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/15563650.2022.2062376</pub-id><pub-id pub-id-type="pmid">35438590</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>West</surname><given-names>PL</given-names></name><name name-style="western"><surname>McKeown</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Hendrickson</surname><given-names>RG</given-names></name></person-group><article-title>Methamphetamine body stuffers: An observational case series</article-title><source>Ann. Emerg. Med.</source><year>2010</year><volume>55</volume><fpage>190</fpage><lpage>197</lpage><pub-id pub-id-type="pmid">19819590</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.annemergmed.2009.08.005</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yal&#231;&#305;n</surname><given-names>M</given-names></name><name name-style="western"><surname>Tunal&#305;</surname><given-names>N</given-names></name><name name-style="western"><surname>Y&#305;ld&#305;z</surname><given-names>H</given-names></name><name name-style="western"><surname>O&#287;uz</surname><given-names>A</given-names></name><name name-style="western"><surname>G&#252;ltekin</surname><given-names>BK</given-names></name></person-group><article-title>Sociodemographic and clinical characteristics of synthetic cannabinoid users in a large psychiatric emergency department in Turkey</article-title><source>J. Addict. Dis.</source><year>2018</year><volume>37</volume><fpage>259</fpage><lpage>267</lpage><pub-id pub-id-type="pmid">31581902</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/10550887.2019.1671146</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boess</surname><given-names>F</given-names></name><name name-style="western"><surname>Ndikum-Moffor</surname><given-names>FM</given-names></name><name name-style="western"><surname>Boelsterli</surname><given-names>UA</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>SM</given-names></name></person-group><article-title>Effects of cocaine and its oxidative metabolites on mitochondrial respiration and generation of reactive oxygen species</article-title><source>Biochem. Pharmacol.</source><year>2000</year><volume>60</volume><fpage>615</fpage><lpage>623</lpage><pub-id pub-id-type="pmid">10927019</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0006-2952(00)00355-5</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dluzen</surname><given-names>DE</given-names></name><name name-style="western"><surname>McDermott</surname><given-names>JL</given-names></name></person-group><article-title>Estrogen, testosterone, and methamphetamine toxicity</article-title><source>Ann. N. Y. Acad. Sci.</source><year>2006</year><volume>1074</volume><fpage>282</fpage><lpage>294</lpage><pub-id pub-id-type="pmid">17105924</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1196/annals.1369.025</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>B&#252;ttner</surname><given-names>A</given-names></name></person-group><article-title>The neuropathology of drug abuse</article-title><source>Neuropathol. Appl. Neurobiol.</source><year>2011</year><volume>37</volume><fpage>118</fpage><lpage>134</lpage><pub-id pub-id-type="pmid">20946118</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2990.2010.01131.x</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>IK</given-names></name><etal/></person-group><article-title>Rhabdomyolysis, acute renal failure, and multiple focal neuropathies after drinking alcohol soaked with centipede</article-title><source>Renal Fail.</source><year>2004</year><volume>26</volume><fpage>93</fpage><lpage>97</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1081/jdi-120028562</pub-id><pub-id pub-id-type="pmid">15083930</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Warner-Smith</surname><given-names>M</given-names></name><name name-style="western"><surname>Darke</surname><given-names>S</given-names></name><name name-style="western"><surname>Day</surname><given-names>C</given-names></name></person-group><article-title>Morbidity associated with non-fatal heroin overdose</article-title><source>Addiction</source><year>2002</year><volume>97</volume><fpage>963</fpage><lpage>967</lpage><pub-id pub-id-type="pmid">12144598</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1360-0443.2002.00132.x</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Green</surname><given-names>AR</given-names></name><name name-style="western"><surname>O'shea</surname><given-names>E</given-names></name><name name-style="western"><surname>Colado</surname><given-names>MI</given-names></name></person-group><article-title>A review of the mechanisms involved in the acute MDMA (ecstasy)-induced hyperthermic response</article-title><source>Eur. J. Pharmacol.</source><year>2004</year><volume>500</volume><fpage>3</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">15464016</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejphar.2004.07.006</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>